# Resume

# Professor Chiranjib Chakraborty, PhD

e-mail:drchiranjib@yahoo.com Phone-+91-9871608125 Skype id: drchiranjib https://scholar.google.com/citations?user=3m8rwpUAAAAJ



#### **SHORT BIOSKETCH**

Dr. Chiranjib Chakraborty is a Professor at the Department of Biotechnology at Adamas University Kolkata. He was a former Professor, Galgotias University, India, and a former Associate Professor, VIT University, Vellore, India. Dr. Chakraborty is also a visiting Professor at Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, South Korea. He has 25 years of research experience, including four years of industrial R& D experience. He has 18 years of teaching experience. At the same time, he is academic editor of iScience, handling/receiving editors of infection, genetics, and evolution, associate editor of 'Frontiers in Pharmacology', 'Frontiers in Bioengineering and Biotechnology,' editor of 'Current Microbiology' and editorial board member of 'Nature Scientific Reports,' 'Interdisciplinary Sciences: Computational Life Sciences,' 'BIOCELL' etc. He has guided 3 Ph.D. students and several B.Tech., M.Tech., and M.Sc. projects. His research interest is Medical bioinformatics/immunoinformatics, noncoding RNA, COVID-19, diabetes, etc. He published more than 184 SCI and Scopus index papers, five books, and two edited books (h-index: 43; i10 index: 96; Citation: 5787 (According to Google Scholar); Cumulative SCI Impact Factor (IF): 792.678; Average SCI Impact Factor: 4.30). He has been listed top 2% of Scientists in the World by Stanford University, USA/Elsevier BV in two consecutive years (2020 and 2021).

#### **CURRENT POSITION**

- Professor, School of Life Science and Biotechnology, Adamas University, Barrackpore –Barasat Rd, Kolkata, India
- Director, Center for Research and Innovation, Adamas University, Barrackpore –Barasat Rd, Kolkata, India
- Visiting Professor, Institute for Skeletal Aging & Orthopedic Surgery, Hallym University, College of Medicine, Chucheon, Gangwondo, South Korea
- Academic Editor / Associate Editor, iScience (Cell press Journal) (IF= 5.458)
- Handling/Receiving Editors, Infection, Genetics and Evolution (Elsevier Journal) (IF= 3.342)

- Associate Editor, Frontiers in Pharmacology (**IF= 5.458**) (specialty section: Experimental Pharmacology and Drug Discovery) (**Frontiers Journal**)
- Associate Editor, Frontiers in Bioengineering and Biotechnology (specialty section: Preclinical Cell and Gene Therapy) (IF= 5.890) (Frontiers Journal)
- Editorial Board Member of more than 10 SCI journals such as Scientific Reports (IF: 4.379) (Nature group); Interdisciplinary Sciences: Computational Life Sciences (Springer) (IF: 2.233); Biocell (IF: 1.254) (2020-till date) and several others.
- Listed top 2% in the Scientists in the world listed by the Stanford University, USA/Elsevier BV in two consecutive years (2020 and 2021).

#### **RESEARCH INTERESTS AND CITATION INDEX**

- **Research interest**: Medical Bioinformatics/Immunoinformatics, COVID-19, ncRNA, Drug targets, Genomics and proteomics in medicine, Diabetes, Therapeutics
- Research Matrix

h-index: 43; i10 index: 96; Citation : 5,787 (According to Google Scholar, March, 2022); 5 Papers with more than 200 citations (i200 index: 5) and 10 Papers with more than 100 citations (i100 index: 10) Scopus h-index: 36; SCI & Scopus indexed Publications: 184; Book Chapters: 09; Cumulative SCI Impact Factor: 792.678; Average SCI Impact Factor: 4.30; Single Author (SCI & Scopus indexed): 4; First Author (SCI & Scopus indexed): 95; Corresponding Author (SCI & Scopus indexed): 115 (Corresponding since 2003); PhD guided: 03 (Degree awarded); Invited talks: 18

#### **PERSONAL INFORMATION**

Name: Chiranjib Chakraborty (As per all Certificates, family name (Surname) spelled as: Chakravartty)

Date of Birth: January 11, 1973 Citizenship: Indian Marital Status: Married

## **PROFESSIONAL EXPERIENCE**

More than 25 years in Scientific Research and Teaching experience in India and aboard.

- Total research experience: 25 Years [including industrial R&D (Industrial Research & Development) experience: **4 years**]
- Total teaching experience: **18 Years**

## ✤ <u>Within India</u>

#### **Positions:**

S. No.	Position held	Name of the Organization	Period
1.	Professor	Adamas University, Kolkata, India	October, 2018- Till Date

2.	Professor	Galgotias University, Greater Noida, India	May, 2012 to September, 2018			
3.	Associate Professor	VIT University, Vellore, India	April, 2010 to April, 2012			
4.	Associate Professor	ofessorGalgotias University,Greater Noida, IndiaMssociate ProfessorVIT University,Vellore, IndiaAssociate ProfessorCollege Of Engineering And Technology, (IILM Academy of Higher Learning), Greater Noida, UP, IndiaJassistant ProfessorCollege Of Engineering And Technology, (IILM Academy of Higher Learning), Greater Noida, UP, IndiaJassistant ProfessorCollege Of Engineering And Technology, (IILM Academy of Higher Learning), Greater Noida, UP, IndiaJassistant ProfessorInstitute of Applied Medicine and Research, UP, IndiaJacsistant ProfessorInstitute of Applied Medicine and Macleods Pharmaceuticals, Mumbai, IndiaMaesearch ScientistGenmark Laboratories, Mumbai, IndiaMaindiaMacleods Pharmaceuticals, Mumbai, IndiaAIndiaMarine Aquarium And Research Centre, ZSI, Digha, WBE	Jan,2009 toApril,2010			
5.	Assistant Professor	College Of Engineering And Technology, (IILM Academy of Higher Learning), Greater Noida, UP, India	July,2005 to Dec, 2008			
6.	Assistant Professor and HOD Institute of Applied Medicine and Research, UP, India		June,2004 to June, 2005			
7.	Sr. Scientist	Genmark Laboratories, Mumbai, India	May,2002 to June,2004			
8.	Research Scientist	Macleods Pharmaceuticals, Mumbai, India	August,2000 to April,2002			
9.	Lecturer (Ad-Hoc)	Burdwan Raj College, Burdwan, WB, INDIA	April,1999 to July,2000			
10.	Junior Research Fellow	Marine Aquarium And Research Centre, ZSI, Digha, WB	December,1995 to April,1999			

## Visiting Position (India)

s.	Position held	Name of the Organization	Period
No.			
1.	Visiting Scientist	Indian Statistical Institute, Kolkata, India	March 12, 2011 to March 21, 2011
2.	Visiting Scientist	Indian Statistical Institute, Kolkata, India	December 02,-2011 to December30,2011
3.	Visiting	Department of Life Science and Biotechnology,	October 27,1998 to November
	<b>Research Fellow</b>	Jadavpur University, Calcutta, India	14,1998

## \* Outside India

S. No.	Position held	Name of the Organization	Period
1.	Visiting	Institute for Skeletal Aging & Orthoepdic Surgery, Hallym	December 2018 to
	<b>Professor</b> University, College of Medicine, Chucheon, Gangwondo, South		January 2019
		Korea	(Approx. one month)
2.	Visiting	Institute for Skeletal Aging & Orthoepdic Surgery, Hallym	May2015 to June 2015
	Professor	University, College of Medicine, Chucheon, Gangwondo, South	(Approx. one month)
		Korea	
3.	Visiting	Institute for Skeletal Aging & Orthoepdic Surgery, Hallym	November2013 to
	Professor	University, College of Medicine, Chucheon, Gangwondo, South	December, 2013

		Korea	(Approx. one month)
4.	Visiting Research Fellow	Department of Computer Sciences, Hong Kong Baptist University, Kowloon Tong, Hong Kong	November, 2014 to December,2014 (Approx. one month)
5.	Sr. Visiting Fellow	Institute of Animal Science and Veterinary Medicine, Chinese Academy of Agricultural Sciences, Beijing 100193, China	October,2009 to December, 2009 (Approx. three months)
6.	Visiting Research Professor	Dept. of Marine Biotechnology and Resources, National Sun Yat-sen University; Kaohisung; Taiwan)	July,2006 to January, 2007 (Six months)
7.	Post Doctoral Fellow	University of Massachusetts, Dartmouth, USA	October, 2002 to December,2003 (One year and one month)

## **ADMINISTRATIVE EXPERIENCE**

S. No.	Position held	Name of the Organization	Period
1.	Vice-Chancellor	Adamas University, Kolkata, India	3 <sup>rd</sup> October 2019
	(Acting)		(For one day)
2.	Dean	School of Life Science and Biotechnology, Adamas	March, 2019 to
		University, Barrackpore –Barasat Rd, Kolkata, India	December, 2019
			(Approx. 10 months)
3.	Director	Innovation Centre, Adamas University, Barrackpore –	October, 2018 to
		Barasat Rd, Kolkata, India	Till date (More than three
			years)
4.	<b>Research Director</b>	Galgotias University, Greater Noida, India	March, 2018 to
			September,2018
			(Six months)
5.	Head, Dept. of	Dept. of Biotechnology, Institute of Applied	July,2004 to
	Biotechnology	Medicines and Research (IAMR) (Under CCS	June, 2005
		University, Meerut, UP), Ghaziabad, UP, India	(More than a year)

#### **EDUCATION**

Language of instruction: English

S. No.	Degree	Board / University	Year of Passing	Remark
1.	Ph.D.	Vidyasagar University (Research work carried in Marine Aquarium and Research Centre (ZSI), WB, India)	2001	Subject: Zoology (Science) [SNAHALATA BANERJEE GOLD MEDAL was awarded in 1999 from Academy of Environmental Biology (India) for adjudicated best-published research award from the PhD work]
2.	Master's Degree: M.Sc in Zoology	Kanpur University (Presently, Chhatrapati Shahu Ji Maharaj University	1995	Subject: Zoology
3.	Bachelor's Degree: B.Sc. (Hons.) in Zoology	The University of Burdwan	1993	Subject: Zoology (Honors), Chemistry (General), Botany (General)

#### **RESEARCH ACHIEVEMENTS**

• Citation

Cumulative Citation Index: 5787; h-Index: 43; i10-index: 96 (citation report based on Google scholar report) 10 Papers with more than 100 citations Google Scholar ID: 3m8rwpUAAAJ Scopus ID: 56219079200 Orcid ID: 0000-0002-3958-239X Web of Science Researcher ID: AAV-1132-2021

#### • Publication Achievements

Total peer reviewed publication: **194** Total SCI Publications: **184** (and **3 SCI book chapters**); Cumulative SCI Impact Factor: **792.678**; Average SCI Impact Factor: **4.30** 

#### • Publication- books

Edited book: 2; Book: 4

#### LIST OF PUBLICATIONS

#### **SCI PUBLICATIONS**

(\*Corresponding Author; \*contributed equally) (Impact Factor=IF)

#### [2022]

184. Sharma AR, S Banerjee, Bhattacharya M, Lee SS, **Chakraborty C\*** (2022) Recent progress of circular RNAs in different types of human cancer: technological landscape, clinical opportunities, and challenges. International Journal of Oncology (\*Corresponding Author) IF: 5.65 (Accepted)

183. Mohapatra RK, El-Shall NA, Tiwari R, Nainu F, Ramana KV, Mohamed TA, **Chakraborty C**, Dhama K (2022) Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: an update. <u>Human Vaccines and Immunotherapeutics</u> IF: 3.452 (Accepted)

182. Bhattacharya M#, Sharma AR, Dhama K, Agoramoorthy G, **Chakraborty C\*#** (2022) Omicron variant (B.1.1.529) of SARS-CoV-2: Understanding mutations in the genome, S-glycoprotein, and antibody binding regions. <u>GeroScience</u> doi: 10.1007/s11357-022-00532-4 (\*Corresponding Author) **IF: 7.713** (# equally contributed) [https://pubmed.ncbi.nlm.nih.gov/35258772/]

181. Bhattacharya M, Sharma AR, Ghosh P, Patra P, Mallick B, Patra BC, Lee SS, **Chakraborty C\*** (2022) TN strain proteome mediated therapeutic target mapping and multi-epitopic peptide-based vaccine development for Mycobacterium leprae. <u>Infection, Genetics and Evolution</u> doi: 10.1016/j.meegid.2022.105245 (\*Corresponding Author) **IF: 3.342** [https://pubmed.ncbi.nlm.nih.gov/35150891/]

180. Mohapatra RK, Tiwari R, Sarangi Ak, Rabiul Islam D, **Chakraborty C**, Dhama K. (2022) Omicron (B.1.1.529) variant of SARS-CoV-2– Concerns, challenges and recent. Journal of Medical Virology. doi: 10.1002/jmv.27633. **IF: 2.327** [https://pubmed.ncbi.nlm.nih.gov/35118666/]

179. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Lee SS\* (2022) A detailed overview of immune escape, antibody escape, partial vaccine escape of SARS-CoV-2 and their emerging variants with escape mutations. <u>Frontiers in Immunology</u> doi: 10.3389/fimmu.2022.801522 (\*Corresponding Author) IF: 7.561

[https://pubmed.ncbi.nlm.nih.gov/35222380/]

178. Bhattacharya M, Sharma AR, Ghosh P, Patra P, Patra BC, Lee SS, **Chakraborty C\*** (2022) Bioengineering of novel non-replicating mRNA (NRM) and self-amplifying mRNA (SAM) vaccine candidates against SARS-CoV-2 using immunoinformatics approach. <u>Molecular Biotechnology</u> doi: 10.1007/s12033-021-00432-6 (\*Corresponding Author) **IF: 2.695** [https://pubmed.ncbi.nlm.nih.gov/34981440/]

177. Ghosh P, Bhattacharya M, Patra P, Sharma G, Patra BC, Lee SS, Sharma AR\*, **Chakraborty C**\* (2022) Evaluation and designing of epitopic-peptide vaccine against Bunyamwera orthobunyavirus using M-polyprotein target sequences. <u>International Journal of Peptide Research and Therapeutics</u> 28(1):5. doi: 10.1007/s10989-021-10322-9 (\*Corresponding Author) **IF: 1.931** [https://pubmed.ncbi.nlm.nih.gov/34867129//]

176. **Chakraborty** C\*, Bhattacharya M, Sharma AR (2022) Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance. <u>Current Opinion in Pharmacology</u> 62:64-73 doi: 10.1016/j.coph.2021.11.006 **IF: 5.547** (\*Corresponding Author) [https://pubmed.ncbi.nlm.nih.gov/34920267/]

175. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Agoramoorthy G\*, Lee SS\* (2022) A Paradigm Shift in the Combination Changes of SARS-CoV-2 Variants and Increased Spread of Delta Variant (B.1.617.2) across the World. <u>Aging and Disease</u> doi: 10.14336/AD.2021.1117 (\*Corresponding Author) **IF: 6.745** 

[http://www.aginganddisease.org/EN/10.14336/AD.2021.1117]

## [2021]

174. **Chakraborty C\***, Sharma AR, Bhattacharya M, Zayed H and Lee SS\* (2021) Understanding gene expression and transcriptome profiling of COVID-19: An initiative towards the mapping of protective immunity genes against SARS-CoV-2 infection. <u>Frontiers in Immunology</u> doi: 10.3389/fimmu.2021.724936 (\*Corresponding Author) **IF: 7.561** [https://pubmed.ncbi.nlm.nih.gov/34975833/]

173. Bhattacharya M, Chatterjee S, Sharma AR, Agoramoorthy G\* and **Chakraborty C**\* (2021) The D614G mutation in S-glycoprotein in SARS-CoV-2 variants and the implication on structure, function, infectivity, immunity, and vaccine escape. <u>Applied Microbiology and Biotechnology</u> doi: 10.1007/s00253-021-11676-2. (\*Corresponding Author) **IF: 4.813** [https://pubmed.ncbi.nlm.nih.gov/34755213/]

172. **Chakraborty C\***, Sharma AR, Bhattacharya M, Agoramoorthy G\* and Lee SS\* (2021) The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: Lessons learned from major clinical studies. <u>Frontiers in Pharmacology</u> 12: 704205. doi: 10.3389/fphar.2021.704205 (\*Corresponding Author) **IF: 5.810** [https://pubmed.ncbi.nlm.nih.gov/34867318/

171. **Chakraborty C\***, Sharma AR, Bhattacharya M, Agoramoorthy G and Lee SS\* (2021) COVID-19 vaccines and vaccination program for aging adults. <u>European Review for Medical and Pharmacological Sciences</u> 25 (21): 6719-6730. doi: 10.26355/eurrev\_202111\_27117 (\*Corresponding Author) **IF: 3.507** [https://pubmed.ncbi.nlm.nih.gov/34787877/]

170. Ohimain EI\*, **Chakraborty C**\* (2021) Editorial: An initiative towards Ebola virus disease (EVD) free world: An edited special anti-infective issue on Ebola Virus Disease. <u>Current Opinion in Pharmacology</u> 62:12-14. doi: 10.1016/j.coph.2021.10.006 **IF: 5.547** (\*Corresponding Author) [https://pubmed.ncbi.nlm.nih.gov/34864559/]

169. **Chakraborty C** (2021) Therapeutics development for Ebola virus disease: A recent scenario. <u>Current Opinion in Pharmacology</u> 60: 208-215. doi: 10.1016/j.coph.2021.07.020. **IF: 5.547** [https://pubmed.ncbi.nlm.nih.gov/34464933/]

168. **Chakraborty** C\*, Sharma AR, Bhattacharya M, Agoramoorthy G and Lee SS\* (2021) Transmission, and mutational landscape of Newly Emerging SARS-CoV-2 Variants. <u>mBio</u> 12(4):e0114021. doi: 10.1128/mBio.01140-21 (\*Corresponding Author) IF: 7.867 [https://pubmed.ncbi.nlm.nih.gov/34465019/]

167. Chakraborty C\*, Saha A, Sharma AR, Bhattacharya M, Lee SS\*, Agoramoorthy G\* (2021) D614G mutation eventuates in all VOI and VOC in SARS-CoV-2: Is it part of the positive selection pioneered by Darwin? Molecular Therapy-Nucleic Acids 26:237-241 doi: 10.1016/j.omtn.2021.07.011. (\*Corresponding Author) IF: 8.886

[https://pubmed.ncbi.nlm.nih.gov/34484868/]

166. Chakraborty C\*, Sharma AR, Bhattacharya M and Lee SS\* (2021) Lessons learned from cuttingedge immunoinformatics on next-generation COVID-19 vaccine research. International Journal of Peptide Research and Therapeutics 27, 2303–2311. doi:10.1007/s10989-021-10254-4 (\*Corresponding Author) IF: 1.931

[https://pubmed.ncbi.nlm.nih.gov/34276266/]

165. Chakraborty C\*, Sharma AR, Bhattacharya M and Lee SS\* (2021) From COVID-19 to cancer mRNA vaccines: moving from bench to clinic in the vaccine landscape. Frontiers in Immunology 12:679344. doi:10.3389/fimmu.2021.679344 (\*Corresponding Author) IF: 7.561 [https://pubmed.ncbi.nlm.nih.gov/34305909/]

164. Sharma G, Alle M, Chakraborty C, Kim JC. (2021) Strategies for transdermal drug delivery against bone disorders: A preclinical and clinical update. Journal of Controlled Release 336:375-395. doi: 10.1016/j.jconrel.2021.06.035. IF: 9.776

[https://pubmed.ncbi.nlm.nih.gov/34175368/]

163. Chakraborty C\*, Bhattacharya M, Sharma AR\* (2021) Present variants of concern (VOC) and variants of interest (VOI) of SARS-CoV-2: their significant mutations in S-glycoprotein, infectivity, reinfectivity, immune escape, and vaccines activity. Reviews in Medical Virology doi:10.1002/rmv.2270 (\*Corresponding Author) IF: 6.989

162. Sarkar BK, Sharma AR, Bhattacharya M, Sharma G, Lee SS\*, Chakraborty C\* (2021) Determination of k-mer density in a DNA sequence and subsequent cluster formation algorithm based on the application of electronic filter. Scientific Reports 11(1):13701. doi: 10.1038/s41598-021-93154-3 (\*Corresponding Author) IF: 4.379 [https://pubmed.ncbi.nlm.nih.gov/34211040/]

161. Shawan MMAK, Sharma AR, Bhattacharya M, Mallik B, Akhter F, Shakil MS, Hossain MM, Banik S, Lee SS\*, Hasan MA\*, Chakraborty C\* (2021) Designing an effective therapeutic siRNA to SARS-CoV-2. silence RdRp of Infection Genetics and Evolution doi: gene 10.1016/j.meegid.2021.104951 (\*Corresponding Author) IF: 3.342 [https://pubmed.ncbi.nlm.nih.gov/34089909/]

160. Chakraborty C\*, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS \* (2021) Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis. Vaccines 9(6): 600. doi: 10.3390/vaccines9060600 (\*Corresponding Author) IF: 4.422 [https://pubmed.ncbi.nlm.nih.gov/34199995/]

159. Chakraborty C\*, Sharma AR, Bhattacharya M, Lee SS, Agoramoorthy G\*(2021) SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection. Annals of Medicine and Surgery doi: 10.1016/j.amsu.2021.102428 (\*Corresponding Author)

[https://pubmed.ncbi.nlm.nih.gov/34109031/]

158. Sharma AR, Bhattacharya M, Bhakta S, Saha A, Lee SS\*, **Chakraborty C\***(2021) Recent research progress on circular RNAs: Biogenesis, properties, functions, and therapeutic potential. <u>Molecular Therapy-Nucleic Acids</u> 25: 355-371 doi: 10.1016/j.omtn.2021.05.022 (\*Corresponding Author) **IF: 8.886** 

[https://pubmed.ncbi.nlm.nih.gov/34484862/]

157. Bhattacharya M, Sharma AR, Ghosh P, Lee SS\*, **Chakraborty C**\*(2021) A next-generation vaccine candidate using alternative epitopes to protect against Wuhan and all significant mutant variants of SARS-CoV-2: an Immunoinformatics approach. <u>Aging and Disease</u> 12(8):2173-2195 doi: 10.14336/AD.2021.0518 (\*Corresponding Author) **IF**: **6.745** [https://pubmed.ncbi.nlm.nih.gov/34881093/]

156. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Agoramoorthy G\*, Lee SS\*(2021) The current second wave and COVID-19 vaccination status in India. <u>Brain Behavior and Immunity</u>. doi:10.1016/j.bbi.2021.05.018 (\*Corresponding Author) IF: 7.217 [https://pubmed.ncbi.nlm.nih.gov/34022371/]

155. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Agoramoorthy G\*, Lee SS\*(2021) All nations must prioritize the COVID-19 vaccination program for elderly adults urgently. <u>Aging and Disease</u> 12 (3): 688-690. doi:10.14336/AD.2021.04026 (\*Corresponding Author) IF: 6.745 [https://pubmed.ncbi.nlm.nih.gov/34094633/]

154. Sharma AR, Sharma G, Bhattacharya M, Lee SS, **Chakraborty C**\*(2021). Circulating miRNA in atherosclerosis: a clinical biomarker and early diagnostic tool. <u>Current Molecular Medicine</u>. doi: 10.2174/1566524021666210315124438. (\*Corresponding Author) IF: 2.222 [https://pubmed.ncbi.nlm.nih.gov/33719955/]

153. Samanta S, Sharma AR, Saha A, Singh MK, Das A, Bhattacharya M, Saha R\*, Lee SS\*, **Chakraborty C**\*.(2021) The bacteriophage Mu lysis system – A new mechanism of host lysis? <u>Biocell</u>. 2021 45(5): 1175-1186 doi:10.32604/biocell.2021.015537 (\*Corresponding Author) **IF: 1.254** [https://www.techscience.com/biocell/v45n5/43075/html]

152. Mallick B, Sharma AR, Bhattacharya M, Lee SS\*, **Chakraborty C\***. (2021) PPAR $\gamma$  LBD and it's ligand specificity reveal selection of potential partial agonist: Molecular dynamics based T2D drug discovery initiative. <u>Biocell</u>. 45(4):953-961. doi:10.32604/biocell.2021.015530 (\*Corresponding Author) IF: 1.254

[https://www.techscience.com/biocell/v45n4/42348]

151. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Lee SS, Agoramoorthy G\* (2021) COVID-19 vaccine: Challenges in developing countries and India's initiatives. <u>Infez Med</u> 29(1):165-166 (\*Corresponding Author) [https://pubmed.ncbi.nlm.nih.gov/33664189/]

150. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Saha RP, Ghosh S, Biswas S, Samanta S, Sharma G, Agoramoorthy G, Lee SS\* (2021) SARS-CoV-2 and other human coronaviruses: Mapping of protease recognition sites, antigenic variation of spike protein and their grouping through molecular phylogenetics.

Infection, Genetics and Evolution 89:104729. doi: 10.1016/j.meegid.2021.104729. (\*Corresponding Author) IF: 3.342 [https://pubmed.ncbi.nlm.nih.gov/33497837/]

149. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Sharma G, Lee SS\* (2021) Immunoinformatics approach for the identification and characterization of T cell and B cell epitopes towards the peptidebased vaccine against SARS-CoV-2. <u>Archives of Medical Research</u> 29:S0188-4409(21)00009-6. (\*Corresponding Author) IF: 2.235 [https://pubmed.ncbi.nlm.nih.gov/33546870/]

148. **Chakraborty C\*,** Bhattacharya M, Mallick B, Sharma AR, Sharma G, Lee SS, Agoramoorthy G\* (2021) SARS-CoV-2 protein drug targets landscape: A potential pharmacological insight view for the new drug development. <u>Expert Review of Clinical Pharmacology</u> 14(2):225-238 doi: 10.1080/17512433.2021.1874348. (\*Corresponding Author) **IF: 5.046** [https://pubmed.ncbi.nlm.nih.gov/33423554/]

147. Ghosh P, Bhakta S, Bhattacharya M, Sharma AR, Sharma G, Lee SS\*, **Chakraborty C\*** (2021) A novel multi-epitopic peptide vaccine candidate against *Helicobacter pylori*: In-silico identification, design, cloning and validation through molecular dynamics.<u>International Journal of Peptide Research and Therapeutics</u>:1-18. doi: 10.1007/s10989-020-10157-w. (\*Corresponding Author) **IF: 1.931** [https://pubmed.ncbi.nlm.nih.gov/33495694/]

146. **Chakraborty C\***, Sharma AR, Mallick B, Bhattacharya M, Sharma G, Lee SS\* (2021) Evaluation of molecular interaction, physicochemical parameters and conserved pattern of SARS-CoV-2 Spike RBD and hACE2: In silico and molecular dynamics approach. <u>European Review for Medical and Pharmacological Sciences</u> 25 (3): 1708-1723 (\*Corresponding Author) **IF: 3.507** [https://pubmed.ncbi.nlm.nih.gov/33629340/]

145. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Sharma G, Saha RP, Lee SS\*. (2021) Ongoing clinical trials of vaccines to fight against COVID-19 pandemic. <u>Immune Network 21:e1</u>. doi: 10.4110/in.2021.21.e5 (\*Corresponding Author) **IF: 6.303** [https://pubmed.ncbi.nlm.nih.gov/33728098/]

144. **Chakraborty C\*,** Sharma AR, Sharma G, Bhattacharya M, Patra BC, Sarkar BK, Banerjee S, Banerjee K, Lee SS\* (2021) Understanding the molecular evolution of tiger diversity through DNA barcoding marker ND4 and NADH dehydrogenase complex using computational biology. <u>Genes Genomics.</u> doi: 10.1007/s13258-021-01089-w. (\*Corresponding Author) **IF: 1.839** [https://pubmed.ncbi.nlm.nih.gov/33884571/]

143. Sharma G, Sharma AR, Bhattacharya M, Lee SS\*, **Chakraborty C**\*(2021) CRISPR/Cas9: A preclinical and clinical perspective for the treatment of human diseases. <u>Molecular-Therapy</u> 29(2):571-586. (\*Corresponding Author) **IF: 11.454** [https://pubmed.ncbi.nlm.nih.gov/33238136/]

142. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS\*, **Chakraborty C\***(2021) Response to: Status of Remdesivir: Not Yet Beyond Question. <u>Archives of Medical Research.</u> 52(1):104-106. doi: 10.1016/j.arcmed.2020.09.005 (\*Corresponding Author) **IF: 2.235** [https://pubmed.ncbi.nlm.nih.gov/32948379/]

#### [2020]

141. **Chakraborty C\***, Agoramoorthy G\* (2020) India's cost-effective COVID-19 vaccine development initiatives. <u>Vaccine</u> 38(50):7883-7884. doi: 10.1016/j.vaccine.2020.10.056. (\*Corresponding Author) **IF: 3.641** 

[https://pubmed.ncbi.nlm.nih.gov/33129610/]

140. **Chakraborty C\***, Sharma AR, Bhattacharya M, Sharma G, Agoramoorthy G, Lee SS\* (2020) Diabetes and COVID-19: A major challenge in Pandemic period? <u>European Review for Medical and Pharmacological Sciences</u> 24(21):11409-11420. doi: 10.26355/eurrev\_202011\_23634. (\*Corresponding Author) **IF: 3.507** [https://pubmed.ncbi.nlm.nih.gov/33215463/]

139. Bhattacharya M, Sharma AR, Mallick B, Sharma G, Lee SS\*, **Chakraborty C\*** (2020) Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex. <u>Infection Genetics and Evolution</u> 85:104587. doi: 10.1016/j.meegid.2020.104587. (\*Corresponding Author) **IF: 3.342** 

[https://pubmed.ncbi.nlm.nih.gov/33039603/]

138. **Chakraborty C\*,** Sharma AR, Sharma G, Lee SS\*(2020) Therapeutic advances of miRNAs: A preclinical and clinical update. Journal of Advanced Research 28:127-138. doi:10.1016/j.jare.2020.08.012 (\*Corresponding Author) IF: 10.479 [https://pubmed.ncbi.nlm.nih.gov/33364050/]

137. Sharma AR, Jagga S, **Chakraborty C**, Lee SS (2020) Fibroblast like Synoviocytes mediates secretion of pro-inflammatory cytokines via ERK and JNK MAPKs in Ti particle induced osteolysis. <u>Materials</u> 13, 3628. <u>IF: 3.623</u> [https://pubmed.ncbi.nlm.nih.gov/32824426/]

136. Saha RP\*, Sharma AR, Singh MK, Samanta S, Bhakta S, Mandal S, Bhattacharya M, Lee SS\*, **Chakraborty C\***. (2020) Repurposing drugs, ongoing vaccine and new therapeutic development initiatives against COVID-19. <u>Frontiers in Pharmacology</u> 11:1258. doi: 10.3389/fphar.2020.01258 (\*Corresponding Author) **IF: 5.810** [https://pubmed.ncbi.nlm.nih.gov/32973505/]

135. Bhattacharya M, Sharma AR, Patra P, Ghosh P, Sharma G, Patra BC, Saha RP, Lee SS\* and **Chakraborty, C\***(2020) A SARS-CoV-2 vaccine candidate: In silico cloning and validation. <u>Informatics in Medicine Unlocked</u> 20: 100394. doi:10.1016/j.imu.2020.100394(\*Corresponding Author) [https://pubmed.ncbi.nlm.nih.gov/32835079/]

134. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Sharma G, Saha RP, Lee SS\*(2020) Extensive partnership, collaboration, and teamwork is required to stop the COVID-19 outbreak. <u>Archives of Medical Research</u> 51(7):728-730. doi: 10.1016/j.arcmed.2020.05.021 (\*Corresponding Author) IF: 2.235 [https://pubmed.ncbi.nlm.nih.gov/32532523/]

133. **Chakraborty** C\*, Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G\* (2020) COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-

#### 2 infected patients. Journal of Medical Virology 92(11):2260-2262.\_\_ doi: 10.1002/jmv.26078. (\*Corresponding Author) IF: 2.327 [https://pubmed.ncbi.nlm.nih.gov/32462717/]

132. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS\*, **Chakraborty C\***(2020) Tocilizumab: A therapeutic option for the treatment of cytokine storm syndrome in COVID-19. <u>Archives of Medical Research</u> 51(6):595-597. doi: 10.1016/j.arcmed.2020.05.009 (\*Corresponding Author) **IF: 2.235** [https://pubmed.ncbi.nlm.nih.gov/32482373/]

131. Saha A, Sharma AR, Bhattacharya M, Sharma G, Lee SS\*, **Chakraborty C\***(2020) Probable molecular mechanism of Remdesivir for the treatment of COVID-19: Need to know more. <u>Archives of Medical Research</u> 51(6):585-586. doi: 10.1016/j.arcmed.2020.05.001 (\*Corresponding Author) **IF: 2.235** [https://pubmed.ncbi.nlm.nih.gov/32439198/]

130. **Chakraborty C\*,** Sharma AR, Bhattacharya M, Sharma G, Lee SS, Agoramoorthy G\*. (2020) Consider TLR5 for new therapeutic development against COVID-19. <u>Journal of Medical Virology</u> 92(11):2314-2315. doi: 10.1002/jmv.25997 (\*Corresponding Author) **IF: 2.327** [https://pubmed.ncbi.nlm.nih.gov/32391920/]

129. **Chakraborty C,** Bhattacharya M. Agoramoorthy G. (2020) Single-cell sequencing of miRNAs: A modified technology. <u>Cell Biology International 44(9):1773-1780</u>. doi: 10.1002/cbin.11376 **IF: 3.612** [https://pubmed.ncbi.nlm.nih.gov/32379363/]

128. Patra P, Bhattacharya M, Ghosh P, Sharma AR, Sharma G, Patra BC, Lee SS\*, Mallick B, **Chakraborty C\*** (2020) Identification and design of a next-generation multi epitopes bases peptide vaccine candidate against prostate cancer: an in silico approach. <u>Cell Biochemistry and Biophysics</u> 78(4):495-509. doi: 10.1007/s12013-020-00912-7 (\*Corresponding Author) **IF: 2.195** [https://pubmed.ncbi.nlm.nih.gov/32347457/]

127. Bhattacharya M, Sharma AR Sharma G, Patra P, Mondal N, Patra BC, Lee SS\*, **Chakraborty C\*** (2020) Computer aided novel antigenic epitopes selection from the outer membrane protein sequences of Aeromonas hydrophila and its analyses. <u>Infection Genetics and Evolution</u> 82:104320. doi: 10.1016/j.meegid.2020.104320. (\*Corresponding Author) **IF: 3.342** [https://pubmed.ncbi.nlm.nih.gov/32298854/]

126. **Chakraborty C\*,** Sharma AR, Sharma G, Lee SS\*. (2020)The interplay among miRNAs, major cytokines, and cancer-related inflammation. <u>Molecular Therapy-Nucleic Acids</u> 20:606-620. doi: 10.1016/j.omtn.2020.04.002. (\*Corresponding Author) **IF: 8.886** [https://pubmed.ncbi.nlm.nih.gov/32348938/]

125. Chakraborty C\*, Sharma AR, Sharma G, Bhattacharya M, Lee SS\*. (2020) SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. European Review for Medical and Pharmacological Sciences 24: 4016-4026 (\*Corresponding Author) IF: 3.507 (More than 100 citations)

[https://pubmed.ncbi.nlm.nih.gov/32329877/]

124. **Chakraborty C\***, Sharma AR, Bhattacharya M, Sharma G, Lee SS\*. (2020) The 2019 novel coronavirus disease (COVID-19) pandemic: A zoonotic prospective. <u>Asian Pacific Journal of Tropical Medicine</u> 13: 242-246 doi:10. 4103/1995-7645.281613\_(\*Corresponding Author) **IF: 1.226** [https://www.apjtm.org/article.asp?issn=1995-

7645;year=2020;volume=13;issue=6;spage=242;epage=246;aulast=Chakraborty#:~:text=On%209th%20J anuary%2C%20the%20Chinese,disease%20(COVID%2D19)]

123. Bhattacharya M, Sharma AR, Patra P, Ghosh G, Sharma G, Patra BC, Lee SS\*, **Chakraborty C\*** (2020) Development of epitope-based peptide vaccine against novel Coronavirus 2019 (SARS-COV-2): Immunoinformatics approach. Journal of Medical Virology 92(6):618-631\_doi:10.1002/jmv.25736 (\*Corresponding Author) IF: 2.327 (More than 270 citations) [https://pubmed.ncbi.nlm.nih.gov/32108359/]

122. Bhattacharya M, Sharma AR, Sharma G, Lee SS\*, **Chakraborty C**\* (2020) Interaction between miRNAs and signaling cascades of WNT pathway in Chronic Lymphocytic Leukemia. <u>Journal of Cellular Biochemistry</u> 121(11):4654-4666. doi:10.1002/jcb.29683. (\*Corresponding Author) **IF: 4.429** [https://pubmed.ncbi.nlm.nih.gov/32100920/]

121. Chakraborty C\*, Sharma A, Sharma G, Bhattacharya M, Lee SS\*. (2020) Insight into evolution and conservation patterns of B1-subfamily members of G-protein-coupled receptors. <u>International Journal of Peptide Research and Therapeutics</u> 1-13. doi:10.1007/s10989-020-10043-5 (\*Corresponding Author) **IF: 1.931** 

[https://pubmed.ncbi.nlm.nih.gov/32421105/]

120. **Chakraborty** C\*, Sharma A, Sharma G, Lee SS\*. (2020) Comparative analysis and molecular evolution of Class I PI3K regulatory subunit  $p85\alpha$  reveal structural similarity between nSH2 and cSH2 domains. International Journal of Peptide Research and Therapeutics 26:2555–2569 (\*Corresponding Author) IF: 1.931

[https://link.springer.com/article/10.1007/s10989-020-10039-1]

119. **Chakraborty** C\*, Sharma A, Sharma G, Bhattacharya M, Lee SS\*. (2020) MicroRNAs: possible regulatory molecular switch controlling the BBB microenvironment. <u>Molecular Therapy-Nucleic Acids</u> 19:933–936. doi:10.1016/j.omtn.2019.12.024 (\*Corresponding Author) **IF: 8.886** [https://pubmed.ncbi.nlm.nih.gov/32004864/]

## [2019]

118. Jagga S, Sharma AR, Chakraborty C\*, Lee SS\*. (2019) Ebola virus disease: Recent advances in diagnostics and therapeutics. <u>Asian Pacific Journal of Tropical Medicine</u>, 12(9), 385-395. IF: 1.226 (\*Corresponding Author)

[https://www.apjtm.org/article.asp?issn=1995-

7645;year=2019;volume=12;issue=9;spage=385;epage=395;aulast=Jagga#:~:text=Ebola%20virus%20dis ease%3A%20Recent%20advances,Asian%20Pac%20J%20Trop%20Med&text=Ebola%20virus%20disea se%20(EVD)%20is,(up%20to%2090%25)]

**117.** Jagga S, Sharma AR, Bhattacharya M, **Chakraborty C**, Lee SS. (2019) Influence of single nucleotide polymorphisms (SNPs) in genetic susceptibility towards periprosthetic osteolysis. <u>Genes</u> <u>Genomics</u> 41(10):1113–1125. **IF: 1.839** [https://pubmed.ncbi.nlm.nih.gov/31313107/]

**116.** Mallick B, Sharma AR, Lee SS\*, **Chakraborty C\***. (2019) Understanding the molecular interaction of human Argonaute-2 and miR-20a complex: a molecular dynamics approach. <u>Journal of Cellular Biochemistry</u> 120(12):19915–19924. (\*Corresponding Author) **IF: 4.429** [https://pubmed.ncbi.nlm.nih.gov/31318096/]

115. Sharma G, Sharma AR, Lee SS, Bhattacharya M, Nam JS, **Chakraborty C\***. (2019) Advances in nanocarriers enabled brain targeted drug delivery across blood-brain barrier. <u>International Journal of Pharmaceutics</u> 559 : 360–372 (\*Corresponding Author) **IF: 5.875** [https://pubmed.ncbi.nlm.nih.gov/30721725/]

## [2018]

114. Kundu SK, **Chakraborty C**, Yagihara S, Teoh SL, Das S. (2018) Anesthetic molecule interaction of noble gases with proteins and lipids and their effect: a review. <u>Current Drug Delivery</u> 15(10):1381-1392. **IF: 2.565** 

[https://pubmed.ncbi.nlm.nih.gov/30124152/]

113. **Chakraborty C\***, Sharma A, Sharma G, Sarkar BK Lee SS\*. (2018) The novel strategies for nextgeneration cancer treatment: miRNA combined with chemotherapeutic agents for the treatment of cancer. <u>Oncotarget</u> 9(11):10164-10174 (\*Corresponding Author) **IF: 5.168** (on the year of publication) [https://pubmed.ncbi.nlm.nih.gov/29515800/]

## [2017]

112. Gupta P, Bhattacharjee S, Sharma AR, Sharma G, Lee SS\*, **Chakraborty C\*.** (2017) miRNAs in Alzheimer disease - a Therapeutic perspective. <u>Current Alzheimer Research.</u> 14(11):1198-1206 (\*Corresponding Author) **IF: 3.500** [https://pubmed.ncbi.nlm.nih.gov/28847283/]

111. **Chakraborty C\***, Sharma A, Sharma G, Doss CG, Lee SS\* (2017) Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. <u>Molecular Therapy-Nucleic Acids</u> 8: 132–143. (\*Corresponding Author) **IF: 8.886 (More than 550 citations)** [https://pubmed.ncbi.nlm.nih.gov/28918016/]

110. Kumar S. Sharma AR, Sharma G, **Chakraborty C**, Kim J (2017) Regulatory functional territory of PLK-1 and their substrates beyond mitosis. <u>Oncotarget</u> 8(23):37942-37962 **IF: 5.168** (on the year of publication)

[https://pubmed.ncbi.nlm.nih.gov/28415805/]

109. Lich TN, Sharma AR, **Chakraborty C**, Saibaba B , Ahn ME, Lee SS. (2017) Review of prospects of biological fluid biomarkers in osteoarthritis. <u>International Journal Molecular Sciences</u> 18(3). pii: E601 **IF: 5.923** 

[https://pubmed.ncbi.nlm.nih.gov/28287489/]

108. Doss CG, Siva R, Christopher BP, Chakraborty C, Zhu H. (2017) Zika: How safe is India? <u>Infectious Diseases of Poverty</u> 6(1):37. IF: 4.520 [https://pubmed.ncbi.nlm.nih.gov/28173851/]

107. **Chakraborty C\***, Mallick B, Sharma AR, Sharma G, Jagga S, George Priya Doss C, Nam JS, Lee SS\*. (2017) Micro-environmental signature of the interactions between druggable target protein, dipeptidyl peptidase-IV, and anti-diabetic drugs. <u>Cell Journal</u> 19(1): 65-83. (\*Corresponding Author) **IF**: **2.479** 

[https://pubmed.ncbi.nlm.nih.gov/28367418/]

106. Nam JS, Sharma AR, Jagga S, Lee DH, Sharma G, Nguyen LT, Lee YH, Chang JD, **Chakraborty C**, Lee SS. (2017) Suppression of osteogenic activity by regulation of WNT and BMP signaling during Titanium particle induced osteolysis. Journal of Biomedical Materials Research Part A 105(3):912-926 **IF: 4.396** 

[https://pubmed.ncbi.nlm.nih.gov/28076890/]

105. Bhattacharya M, Sharma AR, Sharma G, Patra BC, Nam JS, **Chakraborty C\***, Lee SS\*. (2017) The crucial role and regulations of miRNAs in zebrafish development. <u>Protoplasma</u> 254(1):17-31 (\*Corresponding Author) **IF: 3.356** 

[https://pubmed.ncbi.nlm.nih.gov/26820151/]

104. **Chakraborty C**, Lin TS, Das S. (2017) The smart programmable CRISPR technology: a next generation genome editing tool for investigators. <u>Current Drug Targets</u> 18(14):1653-1663. **IF: 3.465** [https://pubmed.ncbi.nlm.nih.gov/27231109/]

103. Thent ZC, **Chakraborty C**, Mahakkanukrauh P, Kosai N, Rajan R, Das S. (2017) The molecular concept of atheromatous plaques. <u>Current Drug Targets</u> 18(11):1250-1258. **IF: 3.465** [https://pubmed.ncbi.nlm.nih.gov/27138760/]

102. Thirumal Kumar D, George Priya Doss C, Sneha P, Tayubi IA, Siva R, **Chakraborty C**, Magesh R. (2017) Influence of V54M mutation in Giant muscle protein titin: A Computational screening and Molecular Dynamics approach. Journal of Biomolecular Structure and Dynamics: 35(5):917-928 **IF: 2.919**(on the year of publication) [https://pubmed.ncbi.nlm.nih.gov/27125723/]

101. Chakraborty C, George Priya Doss C, Zhu H, Agoramoorthy G. (2017) Rising strengths Hong Kong SAR in bioinformatics. Interdisciplinary Sciences-Computational Life Sciences 9(2):224-236. IF: 2.233

[https://pubmed.ncbi.nlm.nih.gov/26961385/]

## [2016]

100. **Chakraborty C**, Chin KY, Das S. (2016) miRNA-regulated cancer stem cells: understanding the property and the role of miRNA in carcinogenesis. <u>Tumor Biology</u> 37(10):13039-13048. **IF: 3.67**(on the year of publication)

[https://pubmed.ncbi.nlm.nih.gov/27468722/]

99. Chakraborty C\*, Sharma AR, Sharma G, Lee SS\* (2016) Zebrafish: A complete animal model to enumerate the nanoparticle toxicity. Journal of Nanobiotechnology 14(1):65. (\*Corresponding Author) IF: 10.435 (More than 150 citations)

[https://pubmed.ncbi.nlm.nih.gov/27544212/]

98. Nagasundaram N, George Priya Doss C, **Chakraborty C**, Karthick V, Thirumal Kumar D, Balaji V, Siva R, Lu A, Zhang G, Zhu H. (2016) Mechanism of artemisinin resistance for malaria PfATP6 L263 mutations and discovering potential antimalarials: An integrated computational approach. <u>Scientific Reports</u> 6:30106. **IF: 4.379** 

[https://pubmed.ncbi.nlm.nih.gov/27471101/]

97. **Chakraborty C**, Das S. (2016) Dynamics of diabetes and obesity: an alarming situation in the developing countries in Asia. <u>Mini-Reviews in Medicinal Chemistry</u> 16(15):1258-1268. **IF: 3.862** [https://pubmed.ncbi.nlm.nih.gov/27145852/]

96. **Chakraborty C\***, Patra BC, Sharma AR, Bhattacharya M, Sharma G, Lee SS\*(2016) MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia. <u>Oncotarget</u> 7 (27), 42683-42697. (\*Corresponding Author) **IF: 6.359** (on the year of publication) [https://pubmed.ncbi.nlm.nih.gov/26967056/]

95. Kumar S. Sharma AR, Sharma G, **Chakraborty C\***, Kim J\* (2016) PLK-1: Angel or Devil for cell cycle progression. <u>Biochimica et Biophysica Acta - Reviews on Cancer</u> 1865(2):190-203 (\*Corresponding Author) **IF: 10.680** [https://pubmed.ncbi.nlm.nih.gov/26899266/]

94. Bhattacharjee S, Sarkar B, Sharma AR, Gupta P, Sharma G, Lee SS\*, **Chakraborty** C\*(2016) Formulation and application of biodegradable nanoparticles based biopharmaceutical delivery - an efficient delivery system. <u>Current Pharmaceutical Design</u> ;22(20):3020-33. (\*Corresponding Author) IF: 3.116

[https://pubmed.ncbi.nlm.nih.gov/26951099/]

93. **Chakraborty C\*,** Wen ZH, Agoramoorthy G, Lin CS\*(2016) Therapeutic microRNA delivery strategies with special emphasis for cancer therapy and tumorigenesis: current trends and future challenges. <u>Current Drug Metabolism</u> 17: 469-477 (\*Corresponding Author) **IF: 3.731** [https://pubmed.ncbi.nlm.nih.gov/26813887/]

92. **Chakraborty C\***, Das S\* (2016) Profiling cell-free and circulating miRNA: A clinical diagnostic tool for different cancers. <u>Tumor Biology</u> 37(5):5705-14. (\*Corresponding Author) **IF: 3.67** (on the year of publication)

[https://pubmed.ncbi.nlm.nih.gov/26831657/]

91. Nam JS, Sharma AR, Nguyen LT, **Chakraborty C**, Sharma G, Lee SS. (2016) Application of bioactive quercetin in oncotherapy: from nutrition to nanomedicine. <u>Molecules</u> 21(1) E108. doi: 10.3390/molecules21010108 **IF: 4.411** 

[https://pubmed.ncbi.nlm.nih.gov/26797598/]

90. Sharma AR, Sharma G, Lee SS\*, **Chakraborty C**\* (2016) miRNA regulated key components of cytokine signaling pathways and inflammation in rheumatoid arthritis. <u>Medicinal Research Reviews</u> 36(3):425-39. (\*Corresponding Author) **IF: 12.944** [https://pubmed.ncbi.nlm.nih.gov/26786912/]

89. Karthick V, Nagasundaram N, Doss CG, **Chakraborty C**, Siva R, Lu A, Zhang G, Zhu H. (2016) Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus. <u>Infectious Diseases of Poverty</u> 5:12 **IF: 4.520** 

[https://pubmed.ncbi.nlm.nih.gov/26888469/]

88. **Chakraborty C**\*, Bandyopadhyay S, Agoramoorthy G\*.(2016) India's computational biology growth and challenges. <u>Interdisciplinary Sciences Computational Life Science</u> 8(3):263-76 (\*Corresponding Author) **IF: 2.233** [https://pubmed.ncbi.nlm.nih.gov/27465042/]

## [2015]

**87.** Chakraborty C. Aging and health - A systems biology perspective. Indian J Med Res. 2015;142(6):776-777. (Invited Book review) (\*Corresponding Author) IF: 1.503 (Book Review: Aging and health - A systems biology perspective, A.I. Yashin, S.M. Jazwinski, editors (Karger, Basel, Switzerland) 2015. 194 pages. Price: US\$ 212.00 / CHF 180.00 ISBN 978-3-318-02729-7.)

[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774080/]

**86.** Sharma G, Sharma AR, Nam JS, GeorgePriya Doss C, Lee SS\*, **Chakraborty** C\*. (2015) Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. Journal of Nanobiotechnology 13:74 (\*Corresponding Author) IF: 10.435 [https://pubmed.ncbi.nlm.nih.gov/26498972/]

**85. Chakraborty C**<sup>\*</sup>, Hsu MJ, Govindasamy Agoramoorthy<sup>\*</sup> (2015) Drug metabolizing enzymes in type II diabetes and their pharmacogenetics during therapy of anti-diabetes drugs. <u>Current Drug Metabolism.</u> 16(10):864-76. (\*Corresponding Author) IF: 3.731 [https://pubmed.ncbi.nlm.nih.gov/26652255/]

**84.** Nagasundaram N, Hailong Z, Liu J, Doss CGP, Vasudevan K, **Chakraborty C**, Chen L (2015) Analyzing the effect of mutation on protein function and discovering potential inhibitors of CDK4: Molecular modelling and dynamics studies. <u>PLoS One</u> 10(8):e0133969. **IF: 3.240** [https://pubmed.ncbi.nlm.nih.gov/26252490/]

**83.** Sarkar BK, **Chakraborty C\***(2015) DNA pattern recognition using canonical correlation algorithm. <u>Journal of Biosciences</u> 40(4)709-719. (\*Corresponding Author) **IF: 1.826** [https://pubmed.ncbi.nlm.nih.gov/26564973/]

**82.** Agoramoorthy G, Chakraborty C(2015) India's budget reduction and AIDS initiatives. Lancet Infectious Diseases 15(6):636 (*Correspondence piece*) IF: 25.071 [https://pubmed.ncbi.nlm.nih.gov/26008839/]

**81.** Bhattacharya M, Sharma AR, Patra B C, Sharma G, Seo EM , Nam JS, **Chakraborty C**\*, Lee SS\*. DNA barcoding to fishes: current status and future directions. <u>Mitochondrial DNA Part A</u> 9:1-9 (\*Corresponding Author) **IF: 1.514** [https://pubmed.ncbi.nlm.nih.gov/26057011/]

**80. Chakraborty C\*,** Doss CGP, Sarin R, Hsu MJ, Agoramoorthy G (2015) Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? -Proposing a new hypothesis. <u>Protoplasma</u> 252(6):1603-10. (\*Corresponding Author) **IF: 3.356** [Erratum: Protoplasma. 2015 Nov;252(6):1611.] [https://pubmed.ncbi.nlm.nih.gov/25698235/]

**79. Chakraborty C**, Doss CGP, Bhatia R, Agoramoorthy G (2015) Profiling of phosphatidylinositol 3kinase (PI3K) proteins in insulin signaling pathway. <u>Applied Biochemistry and Biotechnology</u> 175(7):3431-46. **IF: 2.926** [https://pubmed.ncbi.nlm.nih.gov/25637510/]

**78.** Sudhakar N, George Priya Doss C, Thirumal Kumar D, **Chakraborty C**, Anand K, Suresh M (2015) Deciphering the impact of somatic mutations in exon 20 and exon 9 of *PIK3CA* gene in breast tumors among Indian women through molecular dynamics approach. Journal of Biomolecular Structure and Dynamics 13:1-13 **IF: 2.919** (on the year of publication) [https://pubmed.ncbi.nlm.nih.gov/25679319/]

**77.** Sharma G, Park J, Sharma AR, Jung JS, Kim H, **Chakraborty C**, Song DK, Nam JS, Lee SS (2015) Methoxy poly(ethylene glycol)-poly(lactide) nanoparticles encapsulating quercetin act as an effective anticancer agent by inducing apoptosis in breast cancer. <u>Pharmaceutical Research</u> 32(2):723-35 **IF: 4.200** [https://pubmed.ncbi.nlm.nih.gov/25186442/]

#### [2014]

**76.** Tomar J, **Chakraborty C\***, George Priya Doss C Gera VK (2014) Understanding the conservation patterns and molecular phylogenetics of human death receptors family through computational biology. <u>3</u> <u>Biotech</u> 4(2): 177–187. (\*Corresponding Author) **IF: 2.406** [https://pubmed.ncbi.nlm.nih.gov/28324447/]

75. Agoramoorthy G, **Chakraborty C** (2014) Ebola eradication may need wider partnership. <u>Canadian Medical Association Journal</u> 186(15):1170. (Letter to the editor) **IF: 8.262** [https://pubmed.ncbi.nlm.nih.gov/25332426/]

**74.** Patel P, Basu SK, **Chakraborty C**, Hsu MJ, Agoramoorthy G (2014) India's coastal zone management with an emphasis on rapidly developing Gujarat State. Journal of Coastal Conservation 18( 6) 683-690. **IF: 1.839** [https://link.springer.com/article/10.1007/s11852-014-0344-x]

**73.** Doss CGP, Rajith B, **Chakraboty C**, NagaSundaram N, Shabana Kouser Ali, Hailong Zhu (2014) Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors. <u>Scientific Reports</u> 4: 5868 | DOI: 10.1038/srep05868 **IF: 4.379** [https://pubmed.ncbi.nlm.nih.gov/25091415/]

**72.** Sharma AR#, **Chakraboty C#\***, Lee SS#, Sharma G, Yoon J K, George Priya Doss C, Song DK, Nam JS\* (2014) Computational biophysical, biochemical and evolutionary signature of Human R-spondin Family Proteins, the member of canonical Wnt/β-catenin signaling pathway. <u>BioMed Research International</u> 2014:974316. doi: 10.1155/2014/974316. (\*Corresponding Author) **IF: 3.411** [https://pubmed.ncbi.nlm.nih.gov/25276837/]

**71.** Huang SY, Feng CW, Hung HC, **Chakraborty C**, Chen CH, Chen WF, Jean YH, Wang HM, Sung CS, Sun YM, Wu CY, Liu W, Hsiao CD, Wen ZH. (2014) A novel zebrafish model to provide mechanistic insights into the inflammatory events in carrageenan-induced abdominal edema. <u>PLoS One</u> 9(8): e104414. **IF: 3.240** [https://pubmed.ncbi.nlm.nih.gov/25141004/]

[https://publicd.ncbi.htm.htm.gov/23141004/]

**70. Chakraborty C**, Bandyopadhyay S, Doss CGP, Agoramoorthy G. Exploring genomic roadmap, molecular phylogenetics and association between the MODY cascades using computational biology. <u>Cell</u> <u>Biochemistry and Biophysics</u> 71(3)1491-1502. **IF: 2.194** [https://pubmed.ncbi.nlm.nih.gov/25395195/]

**69. Chakraborty C**, Hsu MJ, Agoramoorthy G (2014) Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with antihyperglycemic drug 'Sitagliptin' and inhibitor 'Diprotin –A'. <u>Cell Biochemistry and Biophysics</u> 70(2):907-22 **IF: 2.194** [https://pubmed.ncbi.nlm.nih.gov/24809328/]

**68.** Chakraboty C#\*, Doss CGP, Bandyopadhyay S# and Agoramoorthy G (2014) Influence of miRNA in insulin signaling pathway and insulin resistance: Micro-molecules with a major role in type-2 diabetes. Wiley Interdisciplinary Reviews-RNA 5:697-712 (\*Corresponding Author) IF: 9.957 (More than 100 citations)

[https://pubmed.ncbi.nlm.nih.gov/24944010/]

**67.** Doss CGP, **Chakraboty C\***, C. Debajyoti, S. Debottam (2014) Understanding sequence similarity and framework analysis between centromere proteins using computational biology. <u>Cell Biochemistry and Biophysics</u> 70(2):897-906. (\*Corresponding Author) **IF: 2.194** [https://pubmed.ncbi.nlm.nih.gov/24839063/]

**66.** Sharma AR, Kundu SK, Nam JS, Sharma G, Doss CGP, Lee SS\*, **Chakraborty C\*** (2014) Next generation delivery system for proteins and genes of therapeutic purpose: why and how? <u>BioMed</u> <u>Research International</u> 2014;2014:327950. doi: 10.1155/2014/327950. (\*Corresponding Author) **IF: 3.411** 

[https://pubmed.ncbi.nlm.nih.gov/25126554/]

**65.** Nam JS#, **Chakraborty C#**, Sharma AR#, Bae KJ, Her H, Sharma G, George Priya Doss C, Lee SS, Hong MS (2014) Effect of WNT3a on keratinocytes utilizing in vitro and bioinformatics analysis. <u>International Journal Molecular Science</u> 15, 5472-5495. **IF: 5.923** [https://pubmed.ncbi.nlm.nih.gov/24686518/]

64. Doss CGP, Chakraboty C, Chen L, Zhu H (2014) Integrating in silico prediction methods, molecular docking, and molecular dynamics simulation to predict the impact of ALK missense mutations in structural perspective. BioMed Research International 2014:895831. doi: 10.1155/2014/895831 IF: 3.411 [https://pubmed.ncbi.nlm.nih.gov/25054154/]

63. Sarkar BK, Sharma AR, Bae KJ, Sharma G, Dutta D, Ding S, Ganbold B, Nam JS, Lee SS, Chakraborty C, Priya Doss C G. (2014) Novel biomarker for prostate cancer diagnosis by MRS. Frontiers in Bioscience (Landmark Ed) 19:1186-201. IF: 4.009 (All Authors have equally contributed) [https://pubmed.ncbi.nlm.nih.gov/24896344/]

62. Doss C CGP, Agoramoorthy G, Chakraboty C\* (2014) TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory. Frontiers in Bioscience (Landmark Ed) 19:1028-40. (\*Corresponding Author) IF: 4.009 [https://pubmed.ncbi.nlm.nih.gov/24896334/]

61. Chakraboty C\*, Doss CGP, Patra BC, Bandyopadhyay S (2014) DNA barcoding to map the directions. microbial communities: current advances and future Applied Microbiology and Biotechnology 98: 3425–3436. (\*Corresponding Author) IF: 4.813 [https://pubmed.ncbi.nlm.nih.gov/24896334/]

60. Doss. CGP, Chakraboty C, Sved Haneef SA, NagaSundaram N, Chen L, Zhu H (2014) Evolutionand structure-based computational strategy reveals the impact of deleterious missense mutations on MODY 2 (maturity-onset diabetes of the young, type 2). Theranostics 4(4):366-385. IF: 11.556 [https://pubmed.ncbi.nlm.nih.gov/24578721/]

59. Doss CGP, Rajith B, Chakraboty C, Balaji V, Magesh R, Gowthami B, Sneha Menon, Swati M, Manjari Trivedi, Jasmine Paul, Richa Vasan, Maitreva Das (2014) In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach. Molecular BioSystems (Molecular Omics) 10(3):421-36. IF: 3.743 [https://pubmed.ncbi.nlm.nih.gov/24336963/]

58. Chakraborty C, Doss CGP, Chen L, Zhu H (2014) Evaluating protein-protein interaction (PPI) networks using in silico pharmacology: to understand the diseases pathway, target discovery and drugdesign. Current Protein & Peptide Science 15(6):561 - 571 IF: 3.272 [https://pubmed.ncbi.nlm.nih.gov/25059326/]

57. Chakraborty C, Agoramoorthy G. (2014) Comparative bioinformatic analysis of the conserved domains, amino acid residues, and binding grooves of tumor necrosis factor. Med Glas (Zenica). 11(1):1-6. IF: 0.202 (on the year of publication) [https://pubmed.ncbi.nlm.nih.gov/24496333/]

56. Chakraborty C, Roy SS, Hsu MJ, Agoramoorthy G (2014) Network analysis of transcription factors for nuclear reprogramming into induced pluripotent stem cell using bioinformatics. Cell Journal 15(4):342-349. IF: 1.983

[https://pubmed.ncbi.nlm.nih.gov/24381858/]

#### [2013]

**55.** Chakraborty C\*, Doss CGP (2013) Crucial protein based drug targets and potential inhibitors for osteoporosis: new hope and possibilities. <u>Current Drug Targets</u> 14(14):1707-13. (\*Corresponding Author) IF: 2.479

[https://pubmed.ncbi.nlm.nih.gov/24144207/]

**54. Chakraborty C\*,** Doss CGP, Bandyopadhyay S (2013) miRNAs in Insulin Resistance and Diabetes-Associated Pancreatic Cancer: The 'Minute and Miracle' Molecule Moving as a Monitor in the 'Genomic Galaxy'. <u>Current Drug Targets</u> 14(10):1110-7 (\*Corresponding Author) (\**Invited article*) **IF: 3.465** [https://pubmed.ncbi.nlm.nih.gov/23834149/]

**53.** Doss CGP, Rajith. B, **Chakraborty C**(2013) Predicting the impact of deleterious mutations in the protein kinase domain of FGFR2 in the context of function, structure, and pathogenesis – A Bioinformatics approach. <u>Applied Biochemistry and Biotechnology</u> 170(8):1853-70. **IF: 2.926** [https://pubmed.ncbi.nlm.nih.gov/23754559/]

**52.** Chakraborty C\*, George Priya Doss C, Bandyopadhyay S, Sarkar BK, Syed Haneef SA (2013) Mapping the structural topology of IRS family cascades through computational biology. <u>Cell</u> <u>Biochemistry and Biophysics</u> 67(3):1319-31. (\*Corresponding Author) IF: 2.194 [https://pubmed.ncbi.nlm.nih.gov/23733669/]

**51.** Chakraborty C, Bandyopadhyay S, Maulik U, Agoramoorthy G. (2013) Topology mapping of insulin-regulated glucose transporter GLUT4 using computational biology. <u>Cell Biochemistry and Biophysics</u> 67(3):1261-74. IF: 2.194 [https://pubmed.ncbi.nlm.nih.gov/23700164/]

**50.** Doss CGP, **Chakraborty C**, Rajith. B, Nagasundaram. N. (2013) Modeling and molecular dynamics approach to characterize the functional nsSNPs in hTERT by means of local DNA sequence context and regularity. Journal of Molecular Modeling 19(9):3517-27. **IF: 1.346** [https://pubmed.ncbi.nlm.nih.gov/23716176/]

**49. Chakraborty C\*,** Doss CGP (2013) Sirtuins family- recent development as a drug target for aging, metabolism, and age related diseases. <u>Current Drug Targets</u> 14(6):666-75. (\*Corresponding Author) (\**Invited article*) **IF: 2.632** [https://pubmed.ncbi.nlm.nih.gov/23614693/]

**48. Chakraborty C\*,** Agrawal A (2013) Computational analysis of C-reactive protein for assessment of molecular dynamics and interaction properties. <u>Cell Biochemistry and Biophysics</u> 67:645-656 (\*Corresponding Author) **IF: 2.074**. [https://pubmed.ncbi.nlm.nih.gov/23494263/]

**47.** Agoramoorthy G, **Chakraborty C** (2013) Is India open to scientific criticism? <u>Current Science</u> 104(4) 406. (*Correspondence piece*) **IF: 1.102** [https://www.currentscience.ac.in/Volumes/104/0406.pdf]

**46.** Doss CGP, Nagasundaram N, **Chakraborty C**, Chen L, Zhu H (2013) Extrapolating the effect of deleterious nsSNPs in the binding adaptability of flavopiridol with CDK7 protein: A Molecular dynamics approach. <u>Human Genomics</u> 7(1):10 **IF: 4.639** 

[https://pubmed.ncbi.nlm.nih.gov/23561625/]

**45. Chakraborty C\*,** Doss CGP,Sharma R, Sahana S, Nair TS (2013) Does computational biology help us to understand the molecular phylogenetics and evolution of cluster of differentiation (CD) proteins? <u>Protein Journal</u> 32(2):143-54. (\*Corresponding Author) (*Highlighted in NewsRx*) **IF: 2.371** [https://pubmed.ncbi.nlm.nih.gov/23344551/]

**44. Chakraborty C\*,** Pal S, Doss CGP, Wen ZH, Lin CS (2013) Nanoparticles as 'smart' pharmaceutical delivery. <u>Frontiers in Bioscience (Landmark Ed)</u> 18, 1030-1050. (\*Corresponding Author) (\*Invited article) **IF: 4.009** 

[https://pubmed.ncbi.nlm.nih.gov/23747865/]

**43.** Tomar J, Gera VK, **Chakraborty C\***(2013) Detection of damaging nsSNPs on human caspasecascades related to apoptotic signalling pathway. <u>Protein and Peptide Letters</u>. 20(9): 982 – 997 (\*Corresponding Author) **IF: 1.890** [https://pubmed.ncbi.nlm.nih.gov/22630344/]

## [2012]

**42. Chakraborty C**, Banerjee S, Banerjee K, Hsu MJ, Agoramoorthy G (2012) Inhibition of leptin receptors through plant-derived ligands for liver fibrosis drug development. <u>Asian Biomedicine</u> 6 (4): 519 – 526. **IF: 0.267** 

[https://sciendo.com/article/10.5372/1905-7415.0604.085]

41. Doss CGP, Nagasundar M, Jain S, **Chakraborty C** (2012) LSHGD: a database for human leprosy susceptible genes. <u>Genomics</u> 100 (3): 162-166 **IF: 5.736** [https://pubmed.ncbi.nlm.nih.gov/22750101/]

**40. Chakraborty** C, Sarkar BK, Patel P, Agoramoorthy G (2012) Information processing in network architecture of genome controlled signal transduction circuit - A proposed theoretical explanation. <u>Theoretical biology forum</u> 105 (1): 67-75 (*Highlighted as newspaper in HighBeam Research; as Health Article in NewsRx*) **IF: 0.071** [https://pubmed.ncbi.nlm.nih.gov/23193798/]

**39.** Chakraborty C\*, Pal S, Doss CGP, Wen ZH, Lin CS (2012) *In Silico* analyses of COMT, an important signaling cascade of Dopaminergic neurotransmission pathway, for drug development of Parkinson's disease. <u>Applied Biochemistry and Biotechnology</u> 167(4):845-60. (\*Corresponding Author) IF: 2.926 [https://pubmed.ncbi.nlm.nih.gov/22622642/]

**38. Chakraborty C**, Roy SS, Hsu MJ, Agoramoorthy G (2012) Can computational biology improve the phylogenetic analysis of insulin? <u>Computer</u> Methods and Programs in Biomedicine 108(2):860-72. **IF: 5.428** (*Highlighted in NewsRx*) [https://pubmed.ncbi.nlm.nih.gov/22622642/]

**37.** Agoramoorthy G, **Chakraborty C.** (2012) Environment: Control electronic waste in India. <u>Nature</u> 485(7398):309. (*Correspondence piece*) **IF: 49.962** [https://pubmed.ncbi.nlm.nih.gov/22596147/]

**36.** Chen WF, **Chakraborty C**, Sung CS, Feng CW, Jean YH, Lin YY, Huang HC, Huang TY, Huang SY, Su TM, Sung PJ, Sheu JH, Wen ZH. (2012) Neuroprotection by marine-derived compound, 11-dehydrosinulariolide in an in vitro Parkinson's model: A promising candidate for the treatment of Parkinson's disease. <u>Naunyn-Schmiedeberg Archives of Pharmacology</u> 385(3):265-75. **IF: 3.000** [https://pubmed.ncbi.nlm.nih.gov/22119889/]

**35.** Chakraborty C, Agoramoorthy G (2012) Stem cells in the light of evolution. Indian J. Medical Research 135:813-819 IF: 2.375 (*Highlighted in NewsRx*) [https://pubmed.ncbi.nlm.nih.gov/22825600/]

**34. Chakraborty C\*,** Tomar J, Gera VK (2012) Conserved domains, residues, WebLogo and active sites of caspase-cascades related to apoptotic signaling pathway. <u>Current Bioinformatics</u> 7(4): 392-401 (\*Corresponding Author) (\**Invited article*) **IF: 3.543** [https://www.eurekaselect.com/104637]

**33.** Tomar J, Gera VK, **Chakraborty C\*** (2012) Can bioinformatic methods inform us about the molecular evolution of different human caspases? <u>Current Bioinformatics</u> 7(4): 402-410(\*Corresponding Author) (\**Invited article*) **IF: 3.543** [https://www.eurekaselect.com/104638/article]

**32.** Lee HY, Magotra M, Wong TY, **Chakraborty C**, Liu JK (2012) ATP-dependent fructose uptake system in *Deinococcus radiodurans*. <u>Applied Microbiology and Biotechnology</u> 93(3):1241-8. **IF: 4.813** [https://pubmed.ncbi.nlm.nih.gov/21822900/]

## [2011]

**31.** Lin YC, Huang SY, Jean YH, Chen WF, Sung CS, Kao ES, Wang HM, **Chakraborty C**, Duh CY, Wen ZH (2011) Intrathecal lemnalol, a natural marine compound obtained from Formosan soft coral, attenuates nociceptive responses and the activity of spinal glial cells in neuropathic rats. <u>Behavioural Pharmacology</u> 22:739–750. **IF: 2.293** 

[https://pubmed.ncbi.nlm.nih.gov/22067479/]

**30.** Kumar SV, Ravunny RK, **Chakraborty C\*** (2011) Conserve domains, conserve residues and surface cavities of C-reactive protein (CRP). <u>Applied Biochemistry and Biotechnology</u> 165:497–505. (\*Corresponding Author) **IF: 2.926** 

[https://pubmed.ncbi.nlm.nih.gov/21541851]

**29. Chakraborty C**, Agoramoorthy G, Hsu MJ (2011) Exploring the evolutionary relationship of insulin receptor substrate family using computational biology. <u>PLoS ONE</u> 6(2): e16580 **IF: 3.240** [https://pubmed.ncbi.nlm.nih.gov/21364910/]

28. Wu GJ, Chen WF, Hung HC, Jean YH, Sung CS, Chakraborty C, Lee HP, Chen NF, Wen ZH (2011) Effects of propofol on proliferation and anti-apoptosis of neuroblastoma SH-SY5Y cell line: New insights into neuroprotection. Brain Research 1384: 42–50. (Highlighted in NewsRx) IF: 3.252 [https://pubmed.ncbi.nlm.nih.gov/21315692/]

27. Chakraborty C, Roy SS, Hsu MJ, Agoramoorthy G (2011) Landscape mapping of functional insulin transduction proteins in signal and insulin resistance: А network based protein-protein interaction analysis. PLoS ONE 6(1): e16388. IF: 3.240 (Highlighted in NewsRx) [https://pubmed.ncbi.nlm.nih.gov/21305025/]

26. Roy SS<sup>#</sup>, Hsu CH, Wen ZH, Lin CS, Chakraborty  $C^{*^{\#}}$  (2011) A hypothetical relationship between the nuclear reprogramming factors for induced pluripotent stem (iPS) cells generation-bioinformatics and algorithmic approach. Medical hypotheses 76(4):507–511. (\*Corresponding Author) (Highlighted in NewsRx) IF: 1.538 [https://pubmed.ncbi.nlm.nih.gov/21195557/]

25. Purushotham D<sup>#</sup>, Ganguly C, Chakraborty C<sup>\*#</sup> (2011) Targeting catechol-o-methyl transferase (COMT) inhibitors for schizophrenia: an approach to target validation and rational drug design. Letters in Drug Design & Discovery 8(2): 246-252. (\*Corresponding Author) (\*Invited article) IF: 1.150 [https://www.eurekaselect.com/87433/article/targeting-catechol-o-methyl-transferase-comt-inhibitorsschizophreniaan-approach]

24. Chakraborty C, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G (2011) Effect of caffeine, norfloxacin and nimesulide on heartbeat and VEGF expression of zebrafish larvae. Journal of Environmental Biology 32(2): 179-183. (*Highlighted in NewsRx*) IF: 0.781 (In the year of publication) [https://pubmed.ncbi.nlm.nih.gov/21882652/]

## [2010]

23. Roy SS, Hsu CH, Wen ZH, Lin CS, Chakraborty C\* (2010) Understanding hematopoietic stem cell mobility pattern through mathematics. Rivista Di Biologia / Theoretical Biology Forum 103(2) 172-180. (\*Corresponding Author) IF: 0.071 [https://pubmed.ncbi.nlm.nih.gov/21449201/]

22. Chakraborty C\*, Roy SS, Hsu CH, Wen ZH, Lin CS\* (2010) Network building of proteins in a biochemical pathway: a computational biology related model for target discovery and drug-design. Current Bioinformatics 5(4):290-295 (\*Corresponding Author) IF: 3.543 [https://www.eurekaselect.com/87254/article/network-building-proteins-biochemical-pathwaycomputational-biology-related-model?tracking-code=3]

21. Chakraborty C\*, Shah KD, Cao WG, Hsu CH, Wen ZH, Lin CS\* (2010) Potentialities of induced pluripotent stem (ips) cells for treatment of diseases. Current Molecular Medicine 10(8):756-62 (\*Corresponding Author) (*Highlighted in NewsRx*) IF: 2.222

[https://pubmed.ncbi.nlm.nih.gov/20937020/]

**20. Chakraborty C\*,** Agoramoorthy G\*(2010) Why zebrafish? <u>Rivista Di Biologia / Theoretical</u> <u>Biology Forum</u> 103(1) 25-28. (\*Corresponding Author) **IF: 0.071** [https://pubmed.ncbi.nlm.nih.gov/21110461/]

**19.** Agoramoorthy G, **Chakraborty C**, Hsu MJ. (2010) Big nation, nano dream-the prospects of India's nanotech revolution. <u>Drug Discovery Today</u> 15(13/14): 495-498 **IF: 7.848** [https://pubmed.ncbi.nlm.nih.gov/20363360/]

**18. Chakraborty C,** Agoramoorthy G (2010) A special report on India's biotech scenario: Advancement in biopharmaceutical and health care sectors. <u>Biotechnology Advances</u> 28: 1–6. **IF: 14.227** [https://pubmed.ncbi.nlm.nih.gov/19931371/]

## [2009]

**17. Chakraborty C\***, Hsu CH, Wen ZH, Lin CS\*(2009) Anticancer drugs discovery and development from marine organisms. <u>Current Topics in Medicinal Chemistry</u> 9(16):1536-45. (\*Corresponding Author) **IF: 3.295** 

[https://pubmed.ncbi.nlm.nih.gov/19903164/]

**16. Chakraborty C\***, Hsu CH, Wen ZH, Duh CY, Lin CS. (2009) Drug discovery from marine resources. <u>Current Science</u> 97(3) 292-293. (\*Corresponding Author) (*Correspondence piece*) **IF: 1.102** [https://www.currentscience.ac.in/Downloads/article\_id\_097\_03\_0292\_0293\_0.pdf]

**15. Chakraborty C\***, Hsu CH, Wen ZH, Lin CS\* (2009) Recent advances of fluorescent technologies for drug discovery and development. <u>Current Pharmaceutical Design</u> 15(30): 3552-3570. (\*Corresponding Author) **IF: 3.116** 

[https://pubmed.ncbi.nlm.nih.gov/19860700/]

**14. Chakraborty C**, Shieh P, Agoramoorthy G (2009) India's stem cell research and development perspectives. International Journal of Hematology 89(3):406-8. IF: 2.490 [https://pubmed.ncbi.nlm.nih.gov/19288172/]

**13. Chakraborty C\***, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G (2009) Zebrafish: A complete animal model for *in vitro* drug discovery and development. <u>Current Drug Metabolism</u> 10(2):116-24 (\*Corresponding Author) **IF: 3.731 (More than 250 citations)** [https://pubmed.ncbi.nlm.nih.gov/19275547/]

**12. Chakraborty C**, B. Sarkar, C.H. Hsu, Z.H. Wen, C.S. Lin, P. C. Shieh (2009) Future prospects of nanoparticles on brain targeted drug delivery. <u>Journal of Neuro-oncology</u> 93(2):285-6. **IF: 4.130** [https://pubmed.ncbi.nlm.nih.gov/19048187/]

## [2008-2003]

**11.** Agoramoorthy G, **Chakraborty C** (2007) Re: introduction to nanotechnology: potential applications in physical medicine and rehabilitation. <u>American Journal of Physical Medicine & Rehabilitation</u>, 86(12):1031-2. **IF: 2.159** [https://pubmed.ncbi.nlm.nih.gov/18090446/]

**10.** Chakraborty C\* (2007) Potentiality of small interfering RNAs (siRNA) as recent therapeutic targets for gene-silencing. Current Drug Targets 8: 479-482. (\*Corresponding Author) IF: 3.465 [https://pubmed.ncbi.nlm.nih.gov/17348839/]

9. Hsu CH, Wen ZH, Lin CS, Chakraborty C \* (2007) Zebrafish model: use in studying cellular mechanisms for a spectrum of clinical disease entities. Current Neurovascular Research 4:111-120. (\*Corresponding Author) (\*Invited article) IF: 1.990 [https://pubmed.ncbi.nlm.nih.gov/17504209/]

8. Chakraborty C\* (2006) Biochemical and molecular basis of insulin resistance. Current Protein and Peptide Science7(2): 113-121. (\*Corresponding Author) IF: 3.272 [https://pubmed.ncbi.nlm.nih.gov/16611137/]

7. Chakraborty C\*, Nandi SS, Sarkar B, Sinha S. (2005) Over-expression and purification of recombinant eel calcitonin and its phylogenetic analysis. Protein and Peptide Letters 12(3) 263-269. (\*Corresponding Author) IF: 1.890 [https://pubmed.ncbi.nlm.nih.gov/15777276/]

6. Chakraborty C\*, Jana S, Nandi SS. (2005) Prion disease: A deadly disease for protein misfolding. Current Pharmaceutical Biotechnology 6(2) 263-269. (\*Corresponding Author) IF: 2.837 [https://pubmed.ncbi.nlm.nih.gov/15853695/]

5. Chakraborty C\*. (2004) Overexpression for commercial production of recombinant human insulin as A- chain and B-chain fusion protein in Escherichia coli through genetic engineered plasmid. Indian Journal of pathology and Microbiology 47(4) 569-573. (\*Corresponding Author) IF: 0.740 [https://pubmed.ncbi.nlm.nih.gov/16295400/]

4. Chakraborty C\*, Nandi S, Sinha S (2004) Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in Streptomyces avermitilis. Protein and Peptide Letters 11(2) 165-173. [PubMed ID: 15078205] (\*Corresponding Author) IF: 1.890 [https://pubmed.ncbi.nlm.nih.gov/15078205/]

3. Jana S, Chakraborty C\*, Nandi S, Deb JK (2004) RNA interface: potential therapeutic targets. Applied Microbiology and Biotechnology 65(6) 649-657. (\*Corresponding Author) (\*Invited article) **IF: 4.813** 

[https://pubmed.ncbi.nlm.nih.gov/15372214/]

2. Jana S, Chakraborty C\*, Nandi S (2004) Mechanism and role of the RNA- based gene silencing. Electronic Journal of Biotechnology 7(3)189-200. (\*Corresponding Author) IF: 2.800 [http://www.bioline.org.br/pdf?ej04037]

1. Chakraborty C\*, Mungantiawar A (2003) Human insulin genome sequence map, biochemical structure of insulin for recombinant DNA insulin. Mini-Reviews in Medicinal Chemistry 3(4) 181-291. (\*Corresponding Author) IF: 3.862

[https://pubmed.ncbi.nlm.nih.gov/12769691/]

## SELECTED NON-SCI PUBLICATIONS (PEER REVIEWED)

**15.** Lin C S., Shih, Jhen Ru, Hsu CH, Wen ZH, **Chakraborty C** (2008) Expression of Green Fluorescence Protein (GFP) in Zebrafish Muscle through Injection: A Gene Therapy Model. Nature Precedings . https://doi.org/10.1038/npre.2008.2718.1

[http://dx.doi.org/10.1038/npre.2008.2718.1]

14. Sarkar, Bimal Kumar, Zen, Wu, Ding, Shangwu, Hsu, C. H., Wen, Z.H., Lin, C. S., and Chakraborty, C. (2008) Micro-magnetic resonance imaging (micro-MRI) study on the sepsis effected eyeball of zebrafish. <u>Nature Precedings.</u> https://doi.org/10.1038/npre.2008.2694.1

[https://doi.org/10.1038/npre.2008.2694.1]

13. Chattopadhyay A and Chakraborty C (1997) Bacterial diseases of African catfish, Clarias gariepinus (Burchell). Fishing Chimes17(6)14.

12. Chakraborty C and Chatterjee T. K. (1998) Assessment of sex ration in the brood stock development pond for optimum production of berried female: A critical factor for continuous seed production in freshwater prawn, Macrobrachium rosenbergii (de Man 13(1)34-36.

11. Chakraborty C and Chattopadhyay A (1998) Turmeric (Curcuma longa) and neem (Azadirachta indica ) in the management of bacterial infection of African catfish, Clarias gariepinus (Burchell). Fishing Chimes18(8)17-18.

10. Chakraborty C and Chattopadhyay A (1997) Ulcerative diseases of fish in southern West Bengal. Trans. Zool Soc. India,1(2)163-164.

**9. C. Chakraborty** and A. Bhatcharyya (2002) Two-step chromatographic: a unique procedure for purification of granulocyte colony stimulating factor (G-CSF) from recombinant *E. coli*. Journal Ecophysiology and Occupation Health, (The Academy of Envrionmental Biology, India) (2) 135-142.

**8.** C. Chakraborty\* and S.Haque (2000): Edible vaccine from transgenic fish. <u>Fishing Chimes</u>, 20(1): 104-105. (\*Corresponding Author)

**7. C. Chakraborty\*** and S. Haque (1999) Immune system and immunization of shrimps. <u>Fishing Chimes</u>, 19(12):21-22. (\*Corresponding Author)

6. C. Chakraborty (1999) Fish vaccination: an overview. Fishing Chimes, 19 (9), 7 -10.

5. C. Chakraborty, T. K.Chatterjee, S. K. Chakraborty (1999) Water quality of larval rearing system of giant freshwater prawn *Macrobrachium rosenbergii* (de Man). <u>Environment and Ecology</u>, 17 (2), 432-435.

4. **C. Chakraborty,** T. K.Chatterjee (1999) Effects of Stocking Density and Light Intensity on Growth and Survival in Larval Rearing of Fresh Water Prawn Macrobrachium rosenbergii (de Man).<u>Environment and Ecology</u>, 17 (2), 288-290.

3. C Chakraborty, TK Chatterjee, SK Chakraborty (1998) Effect of rearing tank background colour on survivability of giant fresh water prawn larvae, Macrobrachium rosenbergii (deMan) <u>Trans. Zool Soc.</u> India,

2. C Chakraborty, TK Chatterjee. (1998) Studies on feeding pattern of fresh water prawn larvae Macrobrachium rosenbergii (deMan) in hatchery system. <u>Trans. Zool Soc. India</u>, 2, 24-29.

1. **C. Chakraborty** and A. K. Chattopadhyay (1998) Ethology of *Oreochromis niloticus* (L) in response to bacterial infection of fins in the fry. <u>Environment & Ecology</u>, 16 (2)385-387.

## **CONFERENCE PROCEEDINGS**

**1. C. Chakraborty** and T. K. Chatterjee (1999) Antibiotic resistant *Aeromonas hydrophila* with R plasmid DNA from larval rearing system of freshwater prawn, *Macrobrachium rosenbergii* (de Man): a treat to aquaculture. Proceeding Environmental Biology(20th Annual Session of the Academy of Environmental Biology Symposium: "Man & Environment : Reflections & vision for future), (The Academy of Environmental Biology, India); 8 (2):217-221. **Best research paper award.** 

#### **BOOK CHAPTER**

#### **International Book Chapter**

5. Bhattacharya, M., Kar, A., Malick, R.C., **Chakraborty, C.**, Das, B.K. and Patra, B.C., 2020. Application of Internet Assistance Computation for Disease Prediction and Bio-modeling: Modern Trends in Medical Science. <u>In Principles of Internet of Things (IoT) Ecosystem: Insight Paradigm</u> (pp. 327-346). (**Springer**) (eBook ISBN 978-3-030-33596-0 Hardcover ISBN 978-3-030-33595-3). [https://link.springer.com/chapter/10.1007/978-3-030-33596-0\_13]

4.Thirumal DK, Judith E, Priyadharshini JC, Siva R, Tayubi IA, **Chakraborty C**, George CP, Zayed H.(2019) Computational and modeling approaches to understand the impact of the Fabry's disease causing mutation (D92Y) on the interaction with pharmacological chaperone 1-deoxygalactonojirimycin (DGJ). <u>Advances in Protein Chemistry and Structural Biology</u> (APCSB) 2019;114:341–407. (**Impact Factor: 3.014**) [PMID: 30635085] (Elsevier) (1876-1623 ISSN) [https://pubmed.ncbi.nlm.nih.gov/30635085/]

3. George Priya Doss C, **Chakraboty C**, Vaishnavi Narayan, Thirumal Kumar. D (2014) Computational approaches and resources in single amino acid substitution analysis towards clinical research. <u>Advances in Protein Chemistry and Structural Biology (APCSB)</u> 94:365-423. (**Impact Factor: 3.014**) [**PMID: 24629192**] (CHAPTER **TEN**) (**Elsevier**) (1876-1623 ISSN) [https://pubmed.ncbi.nlm.nih.gov/24629192/]

2.George Priya Doss C, **Chakraboty C** (2014) Integrating computational methods, molecular docking, and molecular dynamics simulation approaches towards personalized medicine in hematological disorders. Frontiers in Clinical Drug Research-Hematology 277-325 pp. (Bentham e Books; Edited by: <u>Atta-ur-RahmanISBN: 978-1-60805-859-4</u>) (Bentham science publisher)

[https://www.eurekaselect.com/122860/chapter/integrating-computational-methods%2C-molecular-docking%2C-and-molecular-dynamics-simulation-approaches-towards-person]

**1.** George Priya Doss C, **Chakraboty C**, N. Monford Paul Abishek, D. Thirumal Kumar, Vaishnavi Narayanan (2014) Application of evolutionary based in silico methods to predict the impact of single amino acid substitutions in vitelliform macular dystrophy. <u>Advances in Protein Chemistry and Structural Biology (APCSB)</u> 94:177-267. (**Impact Factor: 3.014**) [PMID: 24629188] (CHAPTER SIX) (Elsevier) [https://pubmed.ncbi.nlm.nih.gov/24629188/]

#### National book chapter

4. B. Sarkar, C. Chakraborty (2014) Current Changing Scenario of Biochemistry and Biotechnology in the Perspective of Aquaculture and Animal Biotechnology Advances in biochemistry and biotechnology (Vol.II) (ISBN 978-93-5124-312-0) Aster International (Previously Daya Publishing House, Delhi. India) p1-4.

3. Nandi SS, **Chakraborty C**, Deb J.K.& Gothalwal R (2005) Human granulocyte colony stimulating factor: a therapeutic protein. Advances in biochemistry and biotechnology (Vol.1) (ISBN 81-7035-362-9) Daya Publishing House, Delhi. India; p.53-80.

2. **C. Chakraborty** (2005) From editor desk: Current changing scenario of biotechnology and biochemistry. Advances in biochemistry and biotechnology (Vol.1) (ISBN 81-7035-362-9) Daya Publishing House, Delhi. India; p.1-9.

 $[https://scholar.google.com/scholar?hl=en&as\_sdt=0\% 2C5&q=From+editor+desk\% 3A+Current+changing+scenario+of+biotechnology+and+biochemistry.+Advances+in+biochemistry+and+biotechnology+&btnG=]$ 

1. **C. Chakraborty**, T.K. Chatterjee and S.K. Chakraborty (2000) Development of indigenous larvae rearing method for the seed production of freshwater prawn *Macrobrachium rosenbergii* (de Man). <u>Waste Recycling and Resource Management in the Developing World</u> (Edited by B.B. Jana, R.D. Banerjee, B. Guterstam, I. Heeb),(Proceeding,International Ecological Engineering Society,Swizerland) 149-155. (Kalyani University Pulication)

 $[https://scholar.google.com/scholar?hl=en&as\_sdt=0\% 2C5&q=Development+of+indigenous+larvae+rearing+method+for+the+seed+production+of+freshwater+prawn+Macrobrachium+rosenbergii+\% 28de+Man\% 29.+Waste+Recycling+and+Resource+Management+in+the+Developing+World+&btnG=]$ 

## BOOKs

## **Edited books**

• Sarkar B and Chakraborty C. (2014) Advances in biochemistry and biotechnology (Vol.II) (ISBN 978-93-5124-312-0) Aster International (Previously Daya Publishing House, Delhi. India) p.245

[https://www.amazon.in/Advances-Biochemistry-Biotechnology-Vol-2/dp/9351302741]

 C. Chakraborty (2005) Advances in biochemistry and biotechnology (Vol.I) (ISBN 81-7035-362-9) Daya Publishing House, Delhi. India; p.283. [https://www.abebooks.com/9788170353621/Advances-Biochemistry-Biotechnology-Pt-1-8170353629/plp]

## Books

- **C Chakraborty**, R. Jhingan (2005) Protein based drugs: techno commercial approach (ISBN No. 8176221074) Biotech Books, New Delhi, India. p.194. [https://www.amazon.in/Protein-Based-Drugs-Commercial-Approach/dp/8176221074]
- C. Chakraborty (2004): Production technology of recombinant therapeutic proteins. (ISBN 81-7622-104-X) Biotech Books, New Delhi, India. p267. [https://www.amazon.in/Production-Technology-Recombinant-Therapeutic-Proteins/dp/817622104X]
- C. Chakraborty (2004): Bioinformatics: approaches and applications. (ISBN No. 81-7622-103-1) Biotech Books, New Delhi, India. p.223. [https://www.amazon.in/Bioinformatics-Approaches-Applications-Chiranjib-Chakraborty/dp/8176221031]
- **C. Chakraborty,** A.K. Sadhu. (2001) Biology, hatchery and culture technology of tiger prawn and giant freshwater prawn. (SBN 81-7035-231-2) Daya Publishing House, Delhi. India; p.101. [https://www.amazon.in/Biology-Hatchery-Culture-Technology-Freshwater/dp/8170359767]

## AWARD

- 2021- Chancellor Award (Spirit of Adamas University), Adamas University, Kolkata, India (December, 2021)
- 2021- Research excellence award, Adamas University, Kolkata, India (December, 2021)
- 2021- Dr. Sang-Soo Lee international research award for research excellence in the area of medical bioinformatics for the year 2020 (Award Value: 1 million Korean won deduction of tax (Taxation of

Nonresident Alien)) [Institute for Skeletal Aging and Chuncheon sacred heart hospital, Hallym University, South Korea].

- 2020- AEB-IFI National Award for Excellence in Science [Academy of Environmental Biology, India]
- 2020-Research excellence award, Adamas University, Kolkata, India (December, 2020)
- 2016- Recipient of EET-CRS 4th Academic Brilliance Awards-2016 for Best Researcher in 2016
- 2012- Publication award for 2010 & 2011, VIT University, Vellore, India (contains cash award of 5,000 and a certificate).
- 2010- Publication award, National Sun Yat Sen University, Taiwan (contains cash award of USD 1471 after deduction of tax (Taxation of Nonresident Alien)).
- 1999-Snahalata Banerjee Gold Medal 1998, Academy of Environmental Biology, India for adjudicated best published research award.

## HONORS

- Listed in the World's Top 2% Scientists (2021) (Elsevier BV/Stanford University, USA) (https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/3)
- Session Chair (Afternoon session on 22<sup>nd</sup> April 2021) International e conference on "BIONEXT 2021 : Frontiers on modern biology" during 22- 24 April 2021.
- Convener, International e conference on "BIONEXT 2021 : Frontiers on modern biology" during 22- 24 April 2021
- Listed in the World's Top 2% Scientists (2020) (Elsevier BV/Stanford University, USA) (https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/2) (Ioannidis et al. Updated science-wide author databases of standardized citation indicators. PLoS Biol. 2020 18(10):e3000918. PMID: 33064726)
- Session Chair (Neurobiology session) during the 14th Congress of Federation of Asian and Oceanian Biochemists and Molecular Biologists (FAOBMB) entitled "Current Excitements in Biochemistry and Molecular Biology for Agriculture and Medicine" during 27 30 November 2015 organized by Centre for Cellular and Molecular Biology (CCMB), Hyderabad, Telangana, India.
- Session Chair (Medical biotechnology session) during the seminar entitled "Biogenesis-III" -6th to 7th March 2014, College of Eng and Technology (IILM Academy), Greater Noida
- Technical Committee Member-2nd International Conference on Biomedical Engineering and Biotechnology (iCBEB 2013), to be held in Wuhan, China, on October 11-13, 2013.
- Technical Committee Member-International Symposium on Chemistry and Pharmaceutical Science (CPS), 28-30<sup>th</sup> May, 2012, Macau, China and 2012 International Conference on Biomedical Engineering and Biotechnology (iCBEB) 28th to 30th May 2012, Macau, China
- Technical Committee Member-Spring World Congress on Engineering and Technology (SCET),.26-29<sup>th</sup> May, Xi'on, China 2012
- Guest of Honour and Judge for "Ryan Scientific Mileu", Ryan group of Schools, Ryan International School, Greater Noida
- Member, Excellence Research Group (Biopharmaceutical Innovation) for the Aim for the Top University Plan of National Sun Yat Sen University, Taiwan, 2011
- Technical Committee Member-World Congress on Engineering and Technology (CET)28-30<sup>th</sup> October, 2011, Shanghai, China
- Technical Committee Member, National Conference on Emerging Trends in Applied Science, on September 23-24, 2016.

- Technical Committee Member, 2<sup>nd</sup> National Conference on Emerging Trends in Applied Science, on August 17-18, 2017.
- Organizing Secretary, National Seminar on Biotechnology in Genomic Era: Industrial Priorities. April27-28<sup>th</sup> April, 2006.

#### **TEACHING EXPERIENCE**

More than 18 years of total teaching experience which include teaching assignments at

- 1) Burdwan Raj college, WB, India (1999-2000)
- 2) Institute of Applied Medicines and Research, UP India (2004 2005)
- 3) College of Engineering and Technology, IILM Academy of Higher Learning UP India (2005-2006 and 2007-2010)
- 4) Department of Marine Biotechnology Department of Marine Biotechnology and Resources; National Sun Yat-sen University, Taiwan. (2006-2007)
- 5) Vidyasagar Institute of Education Technology and Research (IILM Academy ),(2007-2010).
- 6) School of Bio-Sciences and Technology, VIT University, Vellore, India (2010-2012)
- 7) Department of Bio-informatics and biochemistry, Galgotias University, India (2012-2018)
- 8) Department of Biotechnology, Adams University, India (October, 2018- Till Date)
- More than 10 years teaching experience in Post Graduate Courses
- Teaching experience comprise the teaching of a number of courses science 1999. These courses are Animal biotechnology, Immunology, Medical Biotechnology, Pharmaceutical Biotechnology, Drug discovery and Development, Bioinformatics, Aquaculture Biotechnology etc. All courses has been taught more that 4/5 semesters.
- Experience in handling Faculty Empowerment Program (FEP) and Fully Flexible Credit System (FFCS) courses

## **RESEARCH EXPERIENCE**

- Total research experience: **25 Years** (including industrial R&D; Industrial Research & Development Experience : **4 years**)
- PhD students: Three (three Ph.D completed, one is working)
- B.Tech. : 25 students, M.Sc. 20 students
- Research projects completed: 5 (five)

## **PATENTS:**

Sr No.	Claim	Inventors	Patent application number and reference number	Application Date:	Applicant	Country of Application
1	A method for	Lee Sang Soo,	Patent application no.	27.04.	Hallym	South Korea
	developing an	Chiranjib	10-2020-0050552	2020.	University	
	epitope-based	Chakravartty,	<b>Reference number</b> :		Industry-	
	peptide vaccine	Ashish Ranjan	P200860		University	
	against	Sharma, Garima			Cooperation	
	SARS-COV-2 virus	Sharma, Manojit			Foundation	

Chiranjib Chakravartty, Ph.D.

		Bhattacharya			(2-2007-	
					019517-5)	
2.	Epitopes isolated	Lee Sang Soo,	Patent application no.	11.12.2020	Hallym	South Korea
	from SARS-CoV-2	Ashish Ranjan	10-2020-0172923		University	
	and coronavirus	Sharma, Garima	<b>Reference number:</b>		Industry-	
	multi-epitopes	Sharma,	P202300		University	
	vaccine composition	Manojit			Cooperation	
	comprising	Bhattacharya,			Foundation	
	the same	Chiranjib				
		Chakravartty				
3.	Epitopes identified	Lee Sang Soo,	Patent application no.	11.12.2020	Applicant	South Korea
	from prostate	Ashish Ranjan	10-2020-0172924		Name:	
	antigen protein and	Sharma, Garima	<b>Reference number:</b>		Hallym	
	prostate cancer	Sharma,	P202350		University	
	multiple-epitopes	Shin Dae Yong,			Industry-	
	vaccine	Manojit			University	
	composition	Bhattacharya,			Cooperation	
	comprising the same	Chiranjib			Foundation	
		Chakravartty				

#### **TECHNOLOGY DEVELOPED**

Sl No.	Name of the Technology	Technology development	Technology transferred to the Industry	Technologies commercialized
1.	Technology for the design and development of an epitope-based peptide vaccine against SARS-COV-2 virus	Technology was Developed and patent applied [process patent ( <b>Patent</b> <b>application no.</b> 10-2020- 0050552 <b>Reference number</b> : P200860)]	Not Available	Not Available
2.	An multi epitope-based peptide vaccine against SARS-COV-2 virus	Patent applied [Vaccine candidate patent( <b>Patent</b> <b>application no.</b> 10-2020- 0172923 <b>Reference number:</b> P202300)]	Discussion going on for technology transferred to an company	
3.	A novel non-replicating mRNA (NRM) and self-amplifying mRNA (SAM) vaccine candidates	Technology developed and patent applying.	Not Available	Not Available
4.	A next-generation vaccine candidate using alternative epitopes to protect against	Technology developed [Research work reference: <b>PMID</b> :	Not Available	Not Available

	Wuhan and all significant mutant variants of SARS-CoV-2	34881093 and PMCID: PMC8612605]		
5.	Multi epitopes bases peptide vaccine candidate against prostate cancer:	Technology developed and patent applied ( <b>Patent application no</b> . 10-2020-0172924 <b>Reference number:</b> P202350)	Not Available	Not Available
7.	An epitopic-peptide vaccine against Bunyamwera orthobunyavirus	Technology developed [Research work reference: <b>PMID:</b> <b>34867129; PMCID:</b> <b>PMC8634745</b> ]	Not Available	Not Available
8.	Multi-epitopic peptide vaccine candidate against <i>Helicobacter pylori</i>	Technology developed Technology developed [Research work reference: PMID: 33495694; PMCID: PMC7816556]	Not Available	Not Available
9.	An antigenic epitopes selection from the outer membrane protein sequences of Aeromonas hydrophila and its analyses with a vaccine construct.	Technology developed Technology developed [Research work reference: <b>PMID:</b> <b>32298854</b> ]	Not Available	Not Available
10.	An assessment of indigenous hatchery technology of freshwater giant prawn, Macrobrachium rosenbergii (de Man) in West Bengal	The technology was developed during my Ph.D. work (1996- 2000/2021)	Not Available	Not Available

#### Note on developed technologies:

# Technology- 1 and Technology- 2. Technology for the design and development of an epitope-based peptide vaccine against the SARS-CoV-2 virus and its multi-epitope vaccine construct

We have developed a vaccine candidate (multi-epitope-based peptide-based vaccine) against SARS-COV-2. It is the first immunoinformatic-based vaccine candidate against SARS-COV-2 throughout the world. This work is wellcited articles in Google Scholar within a year (citation index: more than 270). We have applied for a Korean patent for this innovative approach (Patent application no. 10-2020-0050552 Reference number: P200860) and the vaccine candidate (Patent application no. 10-2020-0172923 Reference number: P202300)

# Technology- 8. An assessment of indigenous hatchery technology of giant freshwater prawn, *Macrobrachium rosenbergii* (de Man)

During my Ph.D. research work, I had developed the hatchery technology of giant freshwater prawn, *Macrobrachium rosenbergii*. The technology was invented, the larval rearing tank shape, tank color, light intensity, brooder selection technology, etc. The antibiotic resistance of bacterial diseases pattern was a significant problem in freshwater prawn hatchery from the larval rearing system, and the antibiotic resistance pattern of bacterial infections was also understood.

#### PhD STUDENTS/ PhD GUIDED

Sl.	Name of the	Thesis Title	Year of	Current position	Remark
No	Student		PhD		

			Award/		
			completion		
1.	Shayam sundar	Cloning, expression	2009	Presently, Dr. Shayam	Shayam sundar Nandi
	Nandi	and purification of		Sundar Nandi is working	received degree from
		granulocyte colony		as Assistant Director and	Guru Ghasidas
		stimulating factor		Sr. Scientist at National	University, India
		(GCSF)		Institute of Virology	Jointly Guided with
				Mumbai Unit, (Indian	Dr. Ragini Gothlwal
				Council of Medical	
				Research(ICMR)),	
				Mumbai	
2.	Jinny Tomar	Structural,	2012	Presently, Dr. Jinny	Jinny Tomar received
		functional and		Tomar is working as	degree from Gautam
		evolutionary		Assistant Professor,	Budha technical
		bioinformatics of		Department of	university ( formerly
		caspases and its		Biotechnology at Amity	U.P. Technical
		receptor		University, Gurgaon,	University, UP, India.
				Haryana	Jointly Guided with
					Dr. VK Gera
3.	Manojit	Characterizations	2019	Presently, Dr. Manojit	Manojit Bhattacharya
	Bhattacharya	and germplasm		Bhattacharya is working	received degree from
		conservation of rare		as Assistant Professor,	Vidyasagar University
		freshwater fish		Department of Zoology at	(WB), India. Jointly
		resources of north-		Fakir Mohan University,	Guided with Professor
		eastern India		Odisha, India	Bidhan Chandra Patra
		through DNA bar-			
		coding			

## **RESEARCH GRANT**

Sl. No	Name of the research grant	Grant amount	Duration	Granting Agency
1.	Cloning, expression and purification of human granulocyte colony stimulating factor (hGCSF)	25 lacks	2003-2006	Glenmark Laboratories, Mumbai
2.	Analysisofstabilityofhumanrecombinantepidermalgrowthfactor(rEGF)withsilversulfadiazinea	1.2 lacks	2003	Glenmark Laboratories, Mumbai

# EDITOR/EDITORIAL ACTIVITIES

• Associate Editor, iScience (Cell press Journal) (IF= 5.458) (2020-till date)

- Receiving Editors, Infection, Genetics and Evolution (Elsevier journal) (IF=3.342) (2020-till date)
- Associate Editor, Frontiers in Bioengineering and Biotechnology (IF= 5.890) (specialty section: Preclinical Cell and Gene Therapy) (2020-till date)
- Associate Editor, 'Frontiers in Pharmacology' (**IF**= **5.810**) (specialty section: Experimental Pharmacology and Drug Discovery) (2010-till date)
- Editor, 'Current Microbiology' (**IF**= **2.188**) (2021-2022)

#### EDITORIAL BOARD MEMBER

- Scientific Reports (Nature group) (2015-till date) (IF= 4.379)
- BIOCELL (Impact Factor =2.82) (2020-till date) (IF= 1.254)
- Interdisciplinary Sciences: Computational Life Sciences(Springer)(2011-till date) (<u>http://www.springer.com/life+sciences/bioinformatics/journal/12539</u>) (IF= 2.233)
- Genomics, Proteomics & Bioinformatics (Elsevier) (2011-2015) (IF= 7.691)
- Current Biotechnology (2012-2014)
- World Journal of Hepatology (2009-2013) (<u>http://www.wjgnet.com/1948-5182/edboard.htm</u>)
- World Journal of Gastrointestinal Pharmacology and Therapeutics (http://www.wjgnet.com) (2010-2018)

(http://www.omicsonline.com/open-access/editorialboard-advanced-chemical-engineering-open-access.php)

- World Journal of Pharmacology (2011-2018) (http://www.wjgnet.com)
- World Journal of Stem Cells (http://www.wjgnet.com) (2011-2018) (http://www.wjgnet.com)

## **GUEST EDITOR FOR SPECIAL ISSUE**

- **Special issue:** Anti-Infectives (2021) (Current Opinion in Pharmacology; **IF: 5.547**) Edited by Elijah Ohimain, Chiranjib Chakraborty
- Special issue: Recent paradigm shift in genomics and proteonomics in medical biology (2015) Frontiers Biosciences (Landmark Ed) (IF: 4.009) (<u>http://www.bioscience.org/special-issue-details?editor\_id=89</u>)

#### **REVIEWER ASSIGNMENT**

ADHOC reviewer more than 25 SCI and Scopus indexed journals

- Reviewer, Lancet (IF: 79.32)
- Reviewer, The Lancet Infectious Diseases(IF: 25.071)
- Reviewer, Nature Biotechnology (IF: 25.071)
- Reviewer, Molecular Cancer (IF: 27.401)
- Reviewer, Aging and diseases (IF: 6.745)
- Reviewer, Frontiers in Immunology (IF: 7.561)
- Reviewer, Reviewer, Frontiers in Pharmacology (IF: 5.810)
- Reviewer, Frontiers in Oncology (IF: 6.244)
- Reviewer, Advanced Science(Wiley-VCH) (IF: 16.804)
- Reviewer, PLoS ONE
- Reviewer, Cell Biochemistry and Biophysics (Springer)

- Reviewer. Applied Biochemistry and Biotechnology(Springer)
- Reviewer, Process Biochemistry (Elsevier)
- Reviewer, Biotechnique
- Reviewer, IET Systems Biology ( Journal from Institution of Engineering and Technology Digital Library)
- Reviewer, BMC Biotechnology (BMC-series journals)
- Reviewer, Environmental Biology of Fishes (Springer)
- Reviewer, Applied Energy (Elsevier)
- Reviewer, Applied Microbiology and Biotechnology (Springer)
- Reviewer, Fish and Shellfish Immunology (Elsevier)
- Reviewer, Preparative Biochemistry & Biotechnology (Taylor & Francis)

Many More

#### MEMBER OF THE COMMITTEE UNIVERSITY / ACADEMIC RESPONSIBILITIES

- Member, Internal Quality Assurance Cell (IQAC), Adamas University (2020-till date)
- Member, Academic Council, Adamas University, India (2019-till date)
- Chairman, Animal Ethics Committee, Adamas University, India (2019-till date)
- Member, Research Advisory Board, Adamas University, India (2019-till date)
- Member, Board of Studies, Department of Biotechnology, Adamas University, India (2019-till date)
- Member, Faculty council, School of Life Science and Biotechnology, Adamas University, India (2019-till date)
- Chairman, Question Paper Moderation Committee, School of Life Science and Biotechnology, Adamas University, India (2019-till date)
- Chairman, Mentorship Committee, Adamas University, India (2019-till date)
- Member, University Research Committee (URC), Galgotias University (2015-2018)
- Member, School Research Committee (SRC) Galgotias University (2017-2018)

## **Invited Lectures**

- 2021: Topics: "Dreaming for India's next-generation bioinformatics and basic research toward 2047" A refresher course (on 'Biotechnology & Bioinformatics' From 16th August to 31st August 2021 supported by UGC-Human Resource Development Centre, NEHU, Shillong) and organized by Department of Biotechnology & Bioinformatics, North Eastern Hill University, India (25th August(9:30 am to 11:00 am) through zoom meeting). Delivered lecture as a resource person.
- 2021: Topics: "Structural Bioinformatics in Drug Discovery" A refresher course (on 'Biotechnology & Bioinformatics' From 16th August to 31st August 2021 supported by UGC-Human Resource Development Centre, NEHU, Shillong) and organized by Department of Biotechnology & Bioinformatics, North Eastern Hill University, India (24th August (11:30 am to 12:30 am) through zoom meeting). Delivered lecture as a resource person.

- 2020: Topics: "Overview of Drug discovery and Development using Bioinformatics : A recent scenario". A webinar organized by Amity Institute of Biotechnology, Amity University, Gurgaon, India (8 th May 2020 Time 2:00 PM through zoom meeting).
- 2015: Topics: "Zebrafish model: an Absolute Animal Model to Study in vitro Drug Discovery, Different Diseases Mechanism and miRNA Research" In: 14th Congress of Federation of Asian and Oceanian Biochemists and Molecular Biologists (FAOBMB) entitled "Current Excitements in Biochemistry and Molecular Biology for Agriculture and Medicine" during 27 - 30 November 2015 organized by Centre for Cellular and Molecular Biology (CCMB), Hyderabad, Telangana, India.
- 2015: Topics: "From bench to market: an overview about the process of drug discovery and development" (Popular lecture) In: "Interdisciplinary approach of Science in Advancement of Technology: Art of human Welfare" during 15-16 October, 2015 organized by Galgotias College of Engineering and Technology, Greater Noida, UP, India.
- **2015:** Topics: "**miRNA-an emerging therapeutic tool for different human diseases**" In: Institute For Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, 200704, Korea; 18<sup>th</sup> June 2015, **South Korea**
- 2014: Topics: "Computational Biology in Genomics and Proteomics Research" *In*: <sup>"</sup>Climate Change, Bioresource & Green Biotechnology" during 12-13 March, 2014 organized by Department of Aquaculture Management & Technology, *Vidyasagar University, Midnapore, West Bengal,* India
- **2014:** Topics: "Application of Computational Biology in Genomics and Proteomics" In: Biogenesis- III -6th March 2014, College of Eng and Technology, (IILM Academy), Greater Noida, India
- **2013:** Topics: "Genomics and Proteomics for Medical Science Research Using Bioinformatics" In: Institute For Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon, 200704, South Korea; 18<sup>th</sup> December,
- 2011: Topics: "Molecular phylogenetics, conserved domain and binding grooves of critical nodes signal-transduction pathway: in a An exploration of insulin signaling pathway". In: Machine Intelligence Unit, Indian Statistical Institute; Kolkata, **India**: 28<sup>th</sup> December
- **2011**: Topics: "Computational Biology in Genomics and Proteomics". In: Department of Zoology, Vidyasagar University; Midnapore, West Bengal, India; 23<sup>rd</sup> August.
- **2007**: Topics: "**Pharmacogenomics and drug discovery**". In International conference and workshop entitled "International conference and workshop of genetics: the basis and diagnosis of genetic disorders". (Organized by: Department of Human Genetics, Sri Ramachandra University, Chennai, India) 1-4<sup>th</sup> Feb.

- 2006: Topics: "Different animal models for drug discovery and development". In: Department of Marine resources & Biotechnology, College of Marine Science, Department of Marine Biotechnology and Resources; National Sun Yat-sen University; Kaohisung; Taiwan. 16<sup>th</sup> November
- **2006**: Topics: "Bioinformatics and drug discovery". In: College of Biological Science, National Sun Yat-sen University; Kaohisung; Taiwan. 5<sup>th</sup> October.
- **2006**: Topics: "**Drug screening and drug discovery from Indian medicinal plant using the zebrafish model**'. In seminar entitled "Development of active pharmaceutical ingredients from Medicinal plants through international cooperation and academic exchanges with India" (Organized by Department of Pharmaceutical Science, Tajen University; Taiwan) 28<sup>th</sup> September.
- 2006: Topics: "From bench to market: Application of drug discovery and development". In seminar entitled "Biohorizon' 2006, the 8th National symposium on Biochemical Engineering and Biotechnology" (Organized by Biochemical Engineers and Technologists Association (BETA), Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, India) 10<sup>th</sup> March
- **2005**: Topics: "**Therapeutics' biotechnology**". In seminar entitled "New Horizons in applied biosciences & entrepreneurship development" (Organized by Indian federation of biotechnologists (IFB) & Indian Institute of Petroleum (CSIR), Dehradun, India 7<sup>th</sup> & 8<sup>th</sup> May.
- **1998**: Topics: "Fish diseases". In: (Organized by Department Agriculture and Food Engineering, Indian Institute of Technology, Kharagpur, India) 23-29<sup>th</sup> November

#### **MEMBERSHIP**

- Senior member, Hong Kong Chemical, Biological& Environmental Engineering Society (HKCBEES)
- International Association of Engineers (IAENG)
- IAENG Society of Bioinformatics, Canada & IAENG Society of HIV/AIDS, Canada
- European Society of Cardiology, France (Working Group on Atherosclerosis and Vascular Biology)
- Indian Science Congress Association (Life member)
- Academy of Environmental Biology (AEB), India (Life member)
- Society of Biological Chemists, India (Life member)
- Indian Association of Aquatic Biologists (IAAB) (Life member)

#### **EVALUATOR/ REVIEWER OF INTERNATIONAL RESEARCH GRANT**

Evaluated several research grants as external reviewer/international reviewer for the following funding agencies:

- British Council in Israel, Israel, 2009
- Association Française contre les Myopathies(AFM), France
- SPARC (Ministry of Human Resource Development), India, 2019

- University of Puerto Rico COVID-19 Grant, Puerto Rico Science, Technology and Research Trust, 2020
- The Wellcome Trust/DBT India Alliance Fellowship, 2021
- The Qatar National Research Fund (QNRF), 2021

## WORKSHOP ATTENDED

- Techniques on molecular biology & biotechnology for insect plant studies, Entomology Research Institute (Loyola College), Chennai, India, 1999. (One month)
- Electron microscopy and its application in biological science, Electron Microscopy Society in India, 1997(One week).

## FACULTY DEVELOPMENT PROGRAMME (FDP) ATTENDED

- FDP on faculty induction training programme, VIT University, Vellore, India, 2010(3 Days)
- FDP on "Microbial Diagnostics, Public Health & Modeling in Health Sciences", VIT University, Vellore, India, 2010(1 Days)
- FDP on "Protein Interactions and Dynamics", VIT University, Vellore, India, 2011(2 Days)
- FDP on "Recent Research Trends in Nano-Biotechnology", VIT University, Vellore, India, 2011(2 Days)

#### MEDIA COVERAGE

1. Snahalata Banerjee Gold Medal, 1998 was highlighted by Fishing Chimes, a magazine of fishery science [Fishing Chimes (1999)19(9)37].

2. An interview was published in Bioimpulse, a life science magazine [Bioimpulse (2007), 1, 40-41].

3. My bioinformatics book (Bioinformatics: Approaches and Applications) was highlighted by The Navhind Times (Navhind Times Science division, August18, 2004)

4. Our research article entitled "Potentialities of induced pluripotent stem (ips) cells for treatment of diseases( <u>Current Molecular Medicine</u> 10(8):756-62)"has been highlighted by NewsRX, a science news publisher in USA. The new has been published by in the Drug Week section (NewsRX) on 11<sup>th</sup> February, 2011.

5. Our research article entitled "Landscape mapping of functional proteins in insulin signal transduction and insulin resistance: A network based protein-protein interaction analysis. (PLoS ONE. 6(1): e16388.)" has been highlighted by NewsRX, a science news publisher in USA. The new has been published by in the Life Science Weekly section (NewsRX) on  $22^{nd}$  March, 2011.

6. Our research article entitled "relationship between the nuclear reprogramming factors for (iPS) cells generation" (<u>Medical hypotheses.</u> 76(4):507–511) has been highlighted by NewsRX, a science news publisher in USA. The new has been published by Biotech Business Week section of NewsRX on 2<sup>nd</sup> May 2011.

7. Our research article entitled "Effect of caffeine, norfloxacin and nimesulide on heartbeat and VEGF expression of zebrafish larvae"(<u>Journal of Environmental Biology</u> 32(2): 179-183) has been highlighted by NewsRX, a science news publisher in USA. The new has been published by NewsRX on 23<sup>rd</sup> May 2011

8. Our research article entitled "effects of propofol on proliferation and anti-apoptosis of neuroblastoma SH-SY5Y cell line: New insights into neuroprotection." (<u>Brain Research</u> 1384: 42–50) has been highlighted by NewsRX, a science news publisher in USA. The new has been published by Biotech Business Week section of NewsRX on 25<sup>nd</sup> May 2011

#### Many more

## References

#### Dr. Govindasamy Agoramoorthy Distinguished Research Processor College of Environmental and Health Sciences, Tajen University, Yanpu, Pingtung 907, Taiwan Tel: 886-916752019; Fax: 886-75253623 E-mail: agoram@tajen.edu.tw, agoram@mail.nsysu.edu.tw

#### 2. Dr. Sang-Soo Lee, M.D., Ph.D.

#### Professor

Director, Institute For Skeletal Ageing, Room No. 3604 College of Medicine, Hallym University, Dept. of Orthopedic Surgery, College of Medicine, Hallym University, Chuncheon Sacred Heart Hospital, 153 Kyo-Dong, Chuncheon, Gangwon-Do 200-704, South Korea Phone ; 82-33-240-5197 Fax: 82-33-252-9875 E-mail: TotalHip@hallym.ac.kr

#### 3. Dr. Bidhan Chandra Patra

#### Professor

Department of Zoology, Vidyasagar University. Midnapore, West Bengal, 721102 India Mobile: + 91 9434185066, Fax: +91 3222 275329 / 275297. E-mail:bcpatra@mail.vidyasagar.ac.in

#### 4. Dr. Dibakar Das

#### **Professor and Dean**

School of Engineering Sciences and Technology (SEST), University of Hyderabad Gachi Bowli, Hyderabad-500046, Telangana India Phone: +91-9581048798 (M), +91-8978339119 (M) E-mail: <u>ddse@uohyd.ernet.in</u>